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Range Adaptive Proton Therapy for Prostate Cancer
Publication No.: ____________
Adam Melancon, M.S.
Supervisory Professor: Lei Dong, Ph.D.

Purpose: The rapid distal falloff of a proton beam allows for sparing of normal
tissues distal to the target. However proton beams that aim directly towards
critical structures are avoided due to concerns of range uncertainties, such as CT
number conversion and anatomy variations. We propose to eliminate range
uncertainty and enable prostate treatment with a single anterior beam by
detecting the proton’s range at the prostate-rectal interface and adaptively
adjusting the range in vivo and in real-time.
Materials and Methods: A prototype device, consisting of an endorectal liquid
scintillation detector and dual-inverted Lucite wedges for range compensation,
was designed to test the feasibility and accuracy of the technique. Liquid
scintillation filled volume was fitted with optical fiber and placed inside the rectum
of an anthropomorphic pelvic phantom.

Photodiode-generated current signal

was generated as a function of proton beam distal depth, and the spatial
resolution of this technique was calculated by relating the variance in detecting
proton spills to its maximum penetration depth. The relative water-equivalent
thickness of the wedges was measured in a water phantom and prospectively
tested to determine the accuracy of range corrections.

Treatment simulation

iii

studies were performed to test the potential dosimetric benefit in sparing the
rectum.
Results: The spatial resolution of the detector in phantom measurement was
0.5 mm. The precision of the range correction was 0.04 mm. The residual
margin to ensure CTV coverage was 1.1 mm. The composite distal margin for
95% treatment confidence was 2.4 mm. Planning studies based on a previously
estimated 2mm margin (90% treatment confidence) for 27 patients showed a
rectal sparing up to 51% at 70 Gy and 57% at 40 Gy relative to IMRT and
bilateral proton treatment.
Conclusion:

We demonstrated the feasibility of our design. Use of this

technique allows for proton treatment using a single anterior beam, significantly
reducing the rectal dose.
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Chapter 1: Introduction
Prostate cancer is the most common malignant neoplasm for males in the
North America with nearly 200,000 new diagnosis and over 25,000 mortalities in
2009 (1). Over the last century, prostate cancer treatment has evolved to allow
curative treatment of the disease without severely affecting the patient’s quality of
life. Nonetheless, locally advanced and metastatic prostate cancer remains a
potential lethal disease, and treatment of early stage disease can potentially
recur adding a substantial monetary burden and reduction of the patient’s quality
and duration of life. Contemporary research aims to definitively treat disease and
incur minimal treatment related side effects in a timely and fiscally responsible
manner. To this end, we will begin with a brief introduction to contemporary
diagnosis and treatment of prostate cancer, the evolution of external beam
therapy, the relation of toxicity with uncertainty and treatment margins, the
resulting advancement of proton therapy, and culminate with our proposed
treatment technique to maximize the advantages of proton therapy for treatment
of the prostate.

1.1 The evolution of external beam photon therapy for prostate cancer
1.1.1 Detection, staging, and modality determination
Early detection is the strongest factor for favorable disease prognosis (2).
Prostate specific antigen (PSA) testing and digital rectal examination are
recommended for screening prostate cancer in men over the age of 50. If the
absolute level of PSA detected in the blood or the PSA level relative to a patient’s
1

previous tests is abnormally high, multiple samples of prostatic tissue are
biopsied from each geographic section of the prostate. Tissue biopsy verifies the
presence of the cancer, identifies the disease’s location for proper tumor staging,
and provides cellular samples for disease prognosis.
By examining the tissue sample from biopsy, the prostate cancer is
graded according to the Gleason scoring system to indicate its level of
aggressiveness and malignancy.

The system ranks the two most prominent

cancer cell types according to their level of cell abnormality, and then adds the
two numbers to generate the Gleason score.

After Gleason scoring, the

disease’s stage is determined with the TNM system.

The TNM staging

determines the progression of the disease within the organ of origin (T), the
regional lymph nodes (N), and distant metastasis (M). Prostate cancer is often
confined to the prostatic capsule; however the malignancy may extend into the
extra-prostatic tissue, seminal vesicles, pelvic lymph nodes, and may
metastasize to skeleton or brain. T2-weighted MRI and bone scans are often
used to supplement CT pelvic scanning and biopsy results for proper tumor
staging.
Based on the previous three tests, patients are assigned a PSA level,
Gleason score, and tumor stage. From these three factors the patients are
stratified according to risk. Low risk prostate cancer is defined as PSA levels of
less than 10 ng/ml, Gleason scores less than 7, and T1 or T2 stage disease on
only one side of the prostate. Intermediate risk cancers have slightly higher PSA
levels (10-20 ng/ml) or a Gleason score of 7.

Seminal vesicle invasion, a
2

Gleason score greater than 7, or a PSA level greater than 20 ml/ng place the
disease within the high risk stratification.
Clinicians consider the disease’s risk classification, the patient’s health,
and treatment side effects when choosing their patient’s treatment modality.
There are several effective treatment options for low-risk locally confined disease
of the prostate including brachytherapy and radical prostatectomy. Both
approaches offer a safe treatment option with an excellent chance of local tumor
control.

Both of these modalities have the potential to spare small critical

structures that are related to the patient’s urinary and reproductive function such
as the penile bulb, neurovascular bundle, and urethra. However, both carry the
risk of leaving residual tumor untreated, the risk of infection, and potentially delay
the patient’s recovery. Additionally, tumor mis-staging is not uncommon, and
locally confined treatments carry the risk of mistreatment of extraprostatic
disease and risk subsequent disease recurrence. For these reasons, external
beam radiation therapy is often used to treat low-risk disease and is the modality
of choice for intermediate and high-risk diseases. . HT is often used as an
adjunct to external beam radiation therapy to ablate the tumor volume
(neoadjuvant hormone therapy, NAD), relieve the patient of disease-related
symptoms, reduce the overall treatment volume thus sparing normal tissue, and
potentially reduce the overall stage of the disease (3). Several studies even
suggest the local control and survival benefits of their combined treatment are
much greater than either treatment alone (4, 5). The exact mechanism for the
observed supra-additive effect of combination radiotherapy and hormone therapy
3

is a topic of debate, however some in vitro evidence suggests that hormone
therapy may potentiate cell death following curative level of radiation dose by
enhancing the cellular apoptotic pathway (6). Our in-house study demonstrated
the dosimetric advantages of post-NAD treatment planning and the risk of
treating based on pre-NAD treatment images (Figure 1).

Figure 1: NAD-induced target volume reduction and the importance of
treatment planning after HT.
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The top left of Figure 1 illustrates the pre-NAD plan on the pre-NAD
anatomy. The top right shows the same plan applied to the anatomy after 108
days of NAD resulting in increased bladder dose with little change of the rectal
and bladder volumes or the rectal dose.

The bottom left illustrates the post-

NAD plan on the post-NAD anatomy. The bottom right shows the post-NAD
coverage of the pre-NAD tumor bed. Areas of both the prostate and SV were not
treated to the full prescription dose. Pre-NAD planning does not ensure coverage
despite its large treatment volume.

1.1.2 Dose-escalated radiotherapy, toxicity, and treatment margins
The escalation of dose to target organs was one of the first and most
critical steps to definitive radiotherapy of advanced prostate carcinoma (7). Early
retrospective studies of dose escalation (8, 9) without the benefit of conformal
technologies indicated that escalated radiation dose may improve survival in
advanced cases. The early Phase I single institution clinical trials of Hanks et al
(10) and Zelefsky et al (11) showed an increased biochemical freedom from
relapse (BNED) among high-risk patients. The Phase III clinical trial by Pollack
et al. (12) showed an improvement in freedom from failure (FFF) within the dose
escalation arm, however this particular study was not sufficiently powered to
demonstrate efficacy of dose escalation in low-risk patients. A more recent study
demonstrated escalation to 79.2 Gy from 70.2 Gy, halved the risk of biochemical
recurrence in 393 patients with disease staged T1b-T2b and PSA levels less
than 15ng/ml (80.4% vs. 61.4% BNED)(13). These studies demonstrated the
benefit of treating with higher dose, even in low-risk disease, to reduce disease
5

recurrence. Survival advantage was difficult to establish in short term studies
with low-risk patient population. However, local control of prostatic disease has
shown to reduce metastatic dissemination(14) and subsequent metastasis-free
survival(15, 16).
Unfortunately, high dose treatment arms in early non-conformal dose
escalation studies resulted in severe rectal complications (17-19). Rectal late
effects included many factors including bleeding, incontinence, diarrhea, oily
discharge, colic, and increased voiding frequency. Non-IMRT dose escalation
trials demonstrated an approximate 2-fold increase in Grade 2 and 3 late rectal
toxicity including two trials with greater than 26% incidence (11-13, 20). A few of
the early trials found correlation of dose with late bladder toxicity (18, 21, 22);
however, most of the following clinical trials found similar bladder toxicity in
escalated and non-escalated treatment arms (12, 13, 23).
The efficacy of dose escalation and the corresponding risk of morbidity for
all disease sites was the impetus for the development of modern conformal
radiotherapy. While two dimensional computer calculations and dose models
were available in the 1960’s, the development of computed tomography (CT) and
the introduction of the beam’s eye view (BEV) concept in the late 1970’s and
early 1980’s let to the development of the first three-dimensional treatment
planning system (24).

3DCRT treatment included physical collimation with

cerrobend or lead blocks attached to the head of the gantry, new plan evaluation
tools such as the dose volume histogram (DVH), and new biological effect
models such as tumor control probability (TCP) and normal tissue complication
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probability (NTCP). These advances improved the therapeutic ratio and allowed,
to some extent, dose escalation without severe adverse effects to surrounding
critical structures.
The emergence of intensity modulated radiation therapy (IMRT) began
with the development of the multi-leaf collimator (MLC).

With the MLC,

collimation could be dynamically changed or segmented to create non-uniform
beam intensities.

New software developments enabled treatment-planning

systems to optimize the beam intensity according to desired dose distribution
input by the user. These advances led to greater conformation of the treatment
field to the tumor (25) and further reduced rectal and bladder dose during therapy
(26, 27).

The highly conformal dose distributions achievable with an IMRT

system made treatment planning highly sensitive to target position uncertainties
(28-30), which led to a need to characterize, immobilize, and localize the target
organs during radiotherapy.
Conformal radiotherapy technologies required a new set of nomenclature
to describe volume-based treatment. ICRU Report 29 was published in 1978,
defining a target volume that included gross tumor, movements, variations, and
uncertainties in treatment (31).

The advent of CT simulation and computer

technology prompted ICRU Report 50, which split the target into 3 parts, the GTV,
CTV, and PTV (32). The GTV included the gross tumor volume, the clinical
target volume (CTV) included the GTV plus uncertainty in microscopic spread,
and the planning target volume (PTV) included the CTV plus geometric (patient
movement and setup) uncertainties. ICRU Report 62 was published in 1999 as a
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supplement to ICRU Report 50(33). This report refined the definition of the PTV
by segregating the single PTV expansion into two expansions of the CTV, one
for organ motion and one for patient set-up and other uncertainties (34).

1.1.3 Treatment uncertainty and its management
Although the ICRU defined the nomenclature used in radiotherapy, the
clinical and research community was still responsible for determining the
uncertainty values and the corresponding treatment margins to apply. The three
primary sources of uncertainty in photon radiotherapy are target volume
delineation, setup error, and organ motion. Since these sources are independent,
the total target uncertainty is approximately the square root of the quadratic sum
of each source. The composite treatment uncertainty is used to calculate the
proper treatment margins to ensure coverage of the treatment target with a
specified statistical confidence, usually 95%. Since the relative amount of dose
the normal tissues receive during treatment and the confidence of target
coverage are directly related to the size of the treatment margins utilized, much
of contemporary medical physics research is aimed at the reduction of treatment
uncertainty to improve the therapeutic ratio of treatment (35).
Treatment uncertainty begins with delineation of the disease volume.
Several factors contribute to the uncertainty in target delineation beginning with
the limitations of the imaging device (36). Many imaging modalities have limited
spatial resolution particularly in the direction perpendicular to the slice plane.
Anatomic information within the coarse voxel is averaged leading to a partial
volume effect. The process of target delineation, i.e. contouring, is also a major
8

source of uncertainty. Repeat contouring of a single physician or contouring
differences between physicians can greatly affect both treatment planning and
dose reporting in radiotherapy.

The most common ways to manage target

delineation uncertainty is with the use of functional imaging (PET, MRI, etc.) coregistered and rendered into CT for improved target definition or the use of
automated delineation, or “segmentation” tools, to improve the consistency of
target definition.
Setup uncertainty involves registration of the external surface of the
patient, the room, and the treatment couch. Patient set-up is achieved with the
use of external immobilization for proper registration of treatment with the
patient’s external anatomy and for reduction of the patient’s movement during the
treatment. Some of the more common external immobilization devices include
the body cradle, thermoplastic shells, knee wedge, and Vac-Lok bag (37-40).
These devices are made of foam or plastics that tightly conform to the patient’s
body, immobilizing them during treatment.
Even with careful immobilization and alignment of the patient, significant
changes occur because of the non-rigidity of anatomy, bowel gas movement,
feces, and the variable filling of the bladder (41-43). Some institutions attempt to
control the fullness or emptiness of the rectum during treatment, and most
institutions treat with a full bladder to improve dosimetry of the bladder wall and
the small bowel and to potentially immobilize the bladder. Although rectal and
bladder filling induced treatment uncertainties are less when treating patients in
the prone position, most institutions elect to treat in the supine position to
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minimize treatment uncertainty caused by respiratory motion (44, 45). Organ
motion is categorized into motions that occur between fractions, interfractional
motion, and those that occur during the fraction, intrafractional motion. Previous
studies indicate that interfractional motion is the greater of the two types of
motion (45), which is fortunate because it is simpler to manage.
One method for the management of interfractional motion is image-guided
target localization. In traditional clinical practice, patient positions are adjusted
based on periodic portal imaging. This localization device consists of a flat-panel
detector attached to the gantry of the linear accelerator, allowing for convenient
megavoltage x-ray imaging of the patient in the treatment position.

Many

corrective and adaptive procedures have been developed for improving
treatment quality including offline correction to the patient’s bony anatomy, online
correction of the patient in conjunction with implanted fiducials, and the
monitoring of motion for future planning adaptation. The disadvantages of the
EPID include poor soft tissue contrast and the lack of proper three dimensional
tissue density information needed for the recalculation of dose. Because of poor
soft tissue contrast of kilo- or mega-voltage x-rays, bony landmarks are generally
used for patient setup. However, bony landmarks do not accurately represent
the positions and shapes of the target and normal tissues. Implanted radioopaque markers may improve registration of the treatment to soft tissue targets
such as the prostate, however, they may exhibit migration or positional instability
when organ shape variation occurs (46, 47). For these reasons, many
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manufacturers have moved to more advanced on-board technologies that
address these limitations (48).
Current clinical practice for prostate radiotherapy also includes the use of
trans-abdominal ultrasound systems (49-51).

The ultrasound system sends and

receives sound waves, which are used to identify the tissue interfaces between
organs for daily target localization. However, inter- and intra-user variability in
the operation of ultrasound devices (52), the inherently poor quality of ultrasound
images, and anatomic distortions resulting from the pressure on the abdomen
(50) reduce the effectiveness of these devices.
An alternative to target localization techniques are internal immobilization
devices. These manage both interfractional and intrafractional motion by
stabilizing the volume of the rectum and bladder. There are a wide variety of
internal immobilization devices for the pelvic anatomy, yet the most common are
catheters, enemas, and balloons. Catheters are used to control the volume of
the bladder, ensuring that the prostate receives the prescribed dose and that the
bladder and small bowel remain out of the high dose region. Rectal balloons and
enemas are used to control rectal filling. An enema empties the rectum of feces
and reduces the generation of gas in the upper bowel. Rectal balloons help
maintain a constant rectal volume during treatment in addition to pushing the
lateral and posterior rectal walls away from the radiation. These may help in
controlling internal soft tissue variations(53-57), however, residual target motion
may still compromise a patient’s daily treatment fraction ,.
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The most precise forms of contemporary target localization are those that
utilize on-board kilovoltage volumetric imaging for precise daily image-guide setup such as “cone-beam” CT (58) and the “CT-on-Rails” (59).

Cone-beam

technology utilizes a point x-ray source and a flat panel detector to reconstruct
three-dimensional objects. The “CT-on-Rails” system is a CT-linear accelerator
combination treatment system that allows for daily diagnostic quality CT tumor
localization without removing the patient from the treatment couch. Both allow
for daily target registration with millimeter precision, however, both methods are
limited by delineation uncertainty, target deformation, and intrafractional
anatomic variation.
Our in-house studies of intrafractional prostate motion addressed the
limitations of on-board CT imaging for daily correction of treatment uncertainties
(60, 61).

We observed anterior and inferior displacement of the target organs

strongly correlated with gaseous build-up of the rectum (P<0.001) in a cohort of
46 prostate cancer patients (Figure 2). The top of figure 2 illustrated an axial
slice of the patient’s anatomy near the base of the prostate and the proximal
seminal vesicles. The arrows indicated the deformation of the patient’s pelvic
anatomy to the image of the patient’s post-fraction CT (bottom). The rectum
expanded shifting prostate and proximal SV anteriorely and superiorly.

The

mean time interval in between CT image acquisitions was 21 minutes. One
standard deviation of anterior displacement was 2.9 mm and 4.1 mm for the
prostate and seminal vesicles respectively. One standard deviation of intra-user
contouring uncertainty was 0.9 and 1.3 mm anteriorely for the prostate and SV
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and 1.4 and 1.7 mm inferiorely for the prostate and SV respectively. These
results suggested that our current margins do not completely correct for
variations of the target during treatment and warranted further investigation.

Figure 2: Intrafractional gaseous build-up in the rectum.
To test the sensitivity of prostate IMRT to intrafractional variations, we
simulated patient treatment on a CT obtained before the patient’s daily treatment
fraction and applied this plan to their post-fraction anatomy. We used a three13

millimeter internal target volume, ITV, based on the results in our first study and
approximation of our current clinical margins that address intrafractional organ
motion. Of 46 patients treated to 75.6 Gy, 3 patient’s prostates and 8 patient’s
seminal vesicles were not covered at the 70 Gy isodose level (92.5% of
prescription). An example is shown in Figure 3. The top of figure 3 illustrates the
deformation field of the pre-fraction anatomy onto the post-fraction anatomy in
the pelvic. Gas migration along with bladder filling has pushed the target organs
(PTV (blue), prostate (red), SV (orange)) anterior and superior to the 60 Gy
isodose and deformed the shape of the target.
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Figure 3: Intrafractional prostate deformation and resultant treatment
fraction.
This study addressed the theoretical limits of what sophisticated on-board
imaging can achieve if used daily before a treatment fraction. Thus, the
treatment margins and resulting therapeutic ratio of external beam radiotherapy
for the prostate has approached a limit of approximately 3 mm. Further
improvement would be extremely difficult without radically improving the way the
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prostate is treated. These limitations have contributed to the development of
proton facilities world-wide to further spare normal tissue and improve treatment
effectiveness.

1.1.4 Summary: The evolution of external beam photon therapy for
prostate cancer
Prostate cancer patients and their physicians may elect numerous ways to
treat prostate cancer, but external beam photon therapy has evolved as a
favorable choice for low risk disease and the preferred choice for intermediate
and high risk diseases when combined with neoadjuvant or concomitant
hormone therapy. Early dose escalation trials with 3DCRT led to unacceptable
morbidities of the rectum and bladder. These treatment morbidities led to the
development of IMRT. Modern conformal radiotherapy was more sensitive to
treatment uncertainty and required new treatment margin definitions. Additional
technologies were developed to reduce target delineation, patient set-up, and
organ motion uncertainties and therefore reduce margins and improve the
therapeutic ratio of treatment.

These technologies included multi-modality

imaging, segmentation tools, external immobilization devices, two dimensional
image-guided localization, internal immobilization devices, and volumetric imageguided target localization.

Even with daily image-guided target localization,

residual uncertainties limited further reduction of margins and improvement of
external photon beam treatment of prostate cancer.

These limitations

contributed to the development of proton facilities world-wide to potentially further
spare normal tissue and improve treatment effectiveness.
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1.2 The development of modern proton therapy for prostate cancer
1.2.1 Advantage of protons to spare normal tissues
The reduction of inter-fractional motion and set-up uncertainty in external
beam photon radiotherapy has led to the reduction of treatment margins, the
ability to escalate target dose for improved local control of disease, and the
reduction of normal tissue doses adjacent to the target organs. However, the
therapeutic ratio of external beam photon therapy is ultimately limited by the
physics of photon attenuation as the photon beam enters, irradiates, and exits
the patient’s body. The depth dose of photons rises abruptly upon entering the
patient and reaches a maximum when the number of charged particles entering a
volume is equivalent to those ionized that exit the volume, a condition known as
electronic equilibrium. This depth can be as great as three centimeters in the
case of 18 MV photons.

Photons attenuate en route to the target volume,

resulting in considerably less absorbed dose inside the target. Photons then
pass though the distal portion of the patients anatomy relatively unimpeded,
resulting in further irradiation of normal tissues as they exit the patient.
Therefore, clinicians utilize multiple beams to spread entrance and exit photon
dose over a large volume of normal tissue. Clinicians assume that these tissues
can tolerate a moderate dose and patients will experience few or no adverse
effects as a result of their treatment.
In the 1940’s, Robert Wilson suggested that proton therapy dose
distribution might result in superior treatment for cancer patients (62). Therapy
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with charged particles can circumvent some of the limitations of photon
radiotherapy treatment. Protons deliver the majority of their dose at the Bragg
peak near the distal end of the beams range. The normal tissue dose is reduced
proximal to the target and eliminated just millimeters distal to the target.
Therefore, proton therapy offers a theoretical advantage over photon therapy for
reducing the irradiated volume of non-target tissues. Additionally, the distal falloff
of a proton beam is considerably sharper than the lateral penumbra of a photon
beam, theoretically allowing for rapid dose falloff near adjacent critical structures
(63).

1.2.2 Proton delivery technology
Passively scattered proton delivery relies on many technologies to deliver
conformal treatment to the entire tumor volume.

The first technology is the

scattering foils which turn a proton pencil beam into a flat field of uniform fluence
at the surface of the target (Figure 4). The first scattering foil spreads the beam
resulting in a wide field with Gaussian fluence. The second scattering foil flattens
the fluence by scattering protons near the center of the field.

The distance

between the first and second foil, second foil and patient, and the lateral scatter
of the protons results in a beam of uniform fluence for a specified source to
surface distance (SSD).
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Figure 4: Dual scatter design to generate a large flat field, (64)
The second technology is the range modulator. The range modulator is a
rotating wheel with varying thickness (steps) of attenuating material that
degrades the initial proton energy to cover the target uniformly from its proximal
to distal end (Figure 5). The relative weighting of each of the Bragg peaks is
computed to generate a uniform treatment of a tumor volume. The sum of these
degraded peaks is termed, the spread out Bragg peak (SOBP). The proper
SOBP width is achieved by gating the proton beam with a specific window of
thickness on the rotating wheel. The same range modulation can be achieved
with spot-scanning systems by directly varying the initial energy of the beam and
weighting these beams appropriately.
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Figure 5: Range modulator wheel
The third technology that allows for conformal proton delivery is range
compensation.

Range compensation corrects for the shape of the patients

surface, tissue inhomogeneites in the beam’s path, and the shape of the distal
target volume. The compensator achieves conformal treatment by degrading the
beam along each ray path to precisely match the distal end of the target volume
(Figure 6). In the absence of heterogeneity along the proton beam-path, the
compensator shape will closely match the shape of the distal edge of the target.
The compensator in figure 5 is much thinner in the area upstream from the highdensity structure to correct for its relatively high radiological thickness.
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Figure 6: Range compensation for conforming a proton beam to the distal
target, (65)

1.2.3 Proton range uncertainty and its management
Since protons deliver their energy over a relatively short area and their
range is highly sensitive to variation in density and proton stopping power along
the path of the beam, management of all set-up and organ motion uncertainties
are critically important. One type of range uncertainty is caused by variation of
tissue heterogeneities, usually air or bone, in the direction perpendicular to the
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beam path. Since the range compensator is unique for each beamlet, variation
in the radiological pathlength to the distal edge of the target will result in a
variation in the proton range and either a loss of dose in the target or
unnecessary dose to distal normal tissues.
In the case of prostate treatment, femur and femoral head rotations have
typically been neglected in positioning studies for prostate cancer patients
because their impact on patient dosimetry is minimal for photon therapy unless
they result in geometric translation of the pelvis or internal pelvic organs.
However, femur and femoral head (FH) rotations may be critical to treatment
uncertainties in prostate proton radiotherapy. We performed an in-house study to
investigate the variation of the femur and femoral heads during treatment and its
effect on bilateral proton treatment (discussed fully in Appendix B). The range
defined by the Bragg peak in proton therapy is roughly proportional to the
radiological path length in the beam path. Range uncertainties in the bilateral
proton therapy of the prostate can potentially compromise the distal coverage of
the target. In addition, dense bony structures, such as the femur and FH, in the
beam path can also cause uncertainties in dose distributions because the Bragg
peak becomes degraded (66). This degradation, in turn, affects the final dose
distribution (67). Hence, depending on the type of immobilization device used,
changes in daily patient setup during the course of proton radiotherapy could
introduce varying amounts of bone in the treatment field due to FH rotation.
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Figure 7: Smearing of a range compensator (68)
It should be noted that in proton radiotherapy “smearing” (68, 69) is
typically applied to the range compensator design in an attempt to resolve the
range uncertainty (Figure 7).

Range compensators are used in proton

radiotherapy to conform the distal edge of each beam to the target while
accounting for the heterogeneities along each beam path. With the appropriate
application of smearing in the design of each compensator, the changes in
radiological path length resulting from tissue motion should not lead to insufficient
proton penetration, thus maintaining distal coverage of the target. However,
compensator smearing is usually two-dimensional and orthogonal to the beam
path, so a significant anatomical rotation may not be fully compensated. To
illustrate this, we designed a single lateral proton beam plan with the greatest
rotational misalignment found in our study (Fig. 8). Figure 8 (a) shows the
reference CT image set and plan in colorwash (top) and linear (bottom) isodose
lines. Figure 8 (b) shows the reference plan recalculated on a daily CT image set
in the Eclipse treatment planning system (Varian Medical Systems, Palo Alto,
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CA). We found that the typical 6.6-mm smearing in our routine proton plan for
prostate treatment did not preserve the dose coverage in this case: The dose
coverage for the prostate dropped from 75.6 Gy (prescription dose) to only 60 Gy.
While a single fraction of treatment with the misaligned FH may not have clinical
impact, a large systematic error in FH position would present a problem. It is
worth mentioning that the dosimetric impact of FH/femur position in proton
therapy cannot be resolved by simply using image-guided setup techniques.
Range uncertainties due to daily radiological path length variations require the
design of better immobilization devices or range verification to ensure accurate
delivery of prescription dose to targets.

a)

b)

Figure 8: Changes in dose distribution after a 20-degree femoral head
rotation.
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Another type of range uncertainty is caused by uncertainties in
determining the relative stopping power ratios for various tissue from CT
Hounsfield units (HU). CT reconstructs the photon linear attenuation coefficient
at each voxel within the patient. The measured HU is then used to determine the
electron density of the material.

Even in homogeneous material, variation in the

HU can be 1 to 2% (70) and up to 3% depending on the location within the
phantom (Moyers 1993). The proton stopping power is then approximated from
the estimated electron density. This approximation is usually accomplished with
a stoichiometric calibration method with tissue equivalent materials described by
Schneider et al (71). Even with rigorous calibration of CT to approximate proton
stopping power, uncertainty in the calculation of the proton’s range persists. If
the stopping power ratio is questionable or the water-equivalent path length
varies, the proton beam may not stop at where you think when designing the
proton treatment. Thus, we apply a generous margin, 3 and one half percent of
the protons total range plus 3 millimeters, to account for the uncertainty in range
calculation from CT Hounsfield units (69)(Figure 9).
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Figure 9: Distal margin applied to a lateral proton beam
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The previous sections discussed the advantages of proton treatment and
the challenges unique to the modality, i.e. range uncertainty. Unfortunately, the
primary tool of protons to maximally spare adjacent critical structures, the abrupt
distal fall-off, cannot be easily utilized in most clinical conditions, such as in the
sparing of the rectum in prostate cancer treatment. This is because the range
uncertainties in proton therapy require large treatment margins and thus limit the
normal tissue sparing capabilities for organs just adjacent to the target. The
range uncertainties are caused by uncertainties in determining the relative
stopping power ratios for living tissues from CT Hounsfield units or the daily
organ variations. The variation of physical depth from variation of the pelvic
anatomy is demonstrated in Figure 10.Figure 10 illustrates interfractional prostate
motion caused by bladder filling in a patient with endorectal balloon
immobilization. Even with the balloon the distance from the anterior rectal wall to
the skin surface at the mid-sagittal slice has increased by more than 1 cm. The
prostate has shifted more than 5 millimeters posteriorely.
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12.01 cm

13.06 cm

Figure 10: Anatomic variation in the depth to the anterior rectal wall
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If the proton beam is directly pointing towards the rectum from the anterior
direction, the range uncertainty of the Bragg peak can either over-irradiate the
rectum or miss the posterior portion of the prostate target (adequate dosing of
the peripheral zone is important in prostate treatment). Therefore, all current
proton treatment techniques for prostate cancer use a lateral beam arrangement
method,(13, 72, 73) which do not fully take the advantage of the sharp fall-off of
proton beams. Proton therapy for prostate cancer using an anterior field is
achievable only if one can accurately control the location of the sharp distal falloff, as illustrated in Figure 11. The proposed anterior proton beam treatment
would utilize the sharp distal fall-off of the proton beam to maximize sparing of
the rectum during radiotherapy.

Figure 11: Prostate treatment using an anterior proton field
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1.2.4 Summary: The development of modern proton therapy for
prostate cancer
Protons deliver sub-maximal dose proximal to the target, maximal dose at
treatment depth, and nearly no dose distal to the target. Therefore, protons have
a theoretical advantage over treatment with photons.

Conformal proton

treatment is achieved with the use of dual scattering foils to generate a flat
fluence profile, range modulator wheel to treat to a volume, and range
compensator to conform a beam to the distal edge of the target organs. The
proton’s range is extremely sensitive to the stopping power of tissues in the path
of the beam. The first source of range uncertainty is variation of heterogeneous
material such as bone and air in the direction perpendicular to the beam path.
Therefore the range compensator designed so that distal coverage of the target
organs is maintained when tissue heterogeneities vary. However, rotations of
highly dense objects, such as the femurs in the treatment of bilateral prostate
treatment, may increase the radiological pathlength beyond those observed at
reference CT and generate mis-coverage in the target organs.

The second

source of uncertainty is determination of proton stopping power from CT
Hounsfield units. A generous distal margin is applied to the target organs to
ensure coverage. The distal margin in conjunction with anatomic variation in the
path of the beam prohibits clinicians from aiming proton beams directly at critical
organs. In the case of the prostate, an anterior proton beam could treat the
target while using its abrupt distal fall-off to maximally spare the rectum.
However, without accurate control of the proton’s range, treatment with the
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anterior beam either risks loss of treatment in the distal prostate or over exposure
of the rectum.
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Chapter 2: Hypothesis and Specific Aims
This chapter will begin with the purpose of the dissertation, state our
hypothesis, state our specific aims to test our hypothesis, and conclude with the
anticipated impact of the dissertation.

2.1 Purpose
The long-term objective of research in radiation oncology is the
improvement of patient treatment, both in terms of biological outcome and quality
of life.

The proposed project has the potential to achieve both, for prostate

cancer patients. The objective of this research is to reduce rectal dose delivered
to patients receiving proton radiotherapy of the prostate, while providing dose
enhancement to the prostate target. To achieve this goal, we will develop a
novel system to reduce proton range uncertainty and enable the treatment of
prostate cancer with an anterior proton beam arrangement. The proposed
system uses a liquid scintillation filled rectal balloon to detect the distal edge of
an anterior proton beam in vivo. The liquid-filled rectal balloon has a dual
function. The first function is to act as an internal immobilization device for the
rectum and the prostate. Liquid-filled rectal balloon will proactively stabilize both
the rectum and the prostate. In addition, measurement of real-time scintillation
light produced by the radiation interacting with the scintillation fluid reaching the
rectum, will allow for continuous adjustment of the proton beam’s fall-off position
with a computerized range shifter. A schematic of the system design is shown in
Figure 12. Real-time range detection and adaptively adjusting the proton
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penetration depth from the anterior beam allows for a minimal distal margin,
resulting in superior rectal sparing over conventional bilateral proton treatment or
IMRT.

Proton
Beam

Controller Box
Stepping motor

A computerized
sliding range shifter

Photodectector

Fiber optic cable
Rectal balloon filled with liquid
scintillation radiation detector
Figure 12: The in vivo proton beam positioning system
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2.2 Hypothesis
The use of in vivo proton beam detection within a rectal balloon and dynamic
range modulation of an anterior proton beam will enable the use of a reduced
distal margin, reducing the mean rectal dose by 20% over conventional bilateral
proton treatment and IMRT.

2.3 Specific Aims
1. Develop an in vivo proton beam detection device located within a rectal
balloon.
Working hypothesis: An in vivo proton beam detection device located within a
rectal balloon can detect the distal fall-off of a proton beam within 2 mm (95%
confidence interval).
2. Develop a computerized external proton beam range shifter to modulate
proton beam energy/range.
Working hypothesis: An external proton beam range shifter can modulate proton
beam energy/range and localize the distal fall-off of a single anterior proton beam
to the anterior rectal wall within 2 mm (95% confidence interval).
3. Determine dosimetric benefit of utilizing the in vivo proton beam
detection device and external proton beam range shifter,
Working hypothesis: Using the measured precision of the in vivo proton beam
detection device and external proton beam range shifter, the reduced margin
planning treatment strategies reduce mean rectal dose by 20% over conventional
bilateral proton and IMRT photon therapies.
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2.4 Impact
The proposed in vivo patient positioning system will have an immediate
impact on the treatment quality of current and future prostate cancer patients.
The ability to spare extra volume of rectum during radiation treatment will
substantially improve the patients’ quality of life by reducing the incidence of
radiation induced rectal toxicity and potentially secondary malignancies.

The

advantages of rectal sparing on patient rectal toxicity and quality of life were
demonstrated with widespread adoption of IMRT over 3D-conformal photon
therapy (26, 27, 74). Several studies have quantified the relation dose-volume in
the rectum with probability of rectal toxicity and suggest that rectal toxicity is
directly tied to volume of the rectum receiving near prescription doses (53, 7578)). Conventional bilateral proton treatment provides little improvement over
IMRT, with the exception in the low dose region. Our proposed anterior beam
treatment substantially improves rectal sparing over both modalities. This
treatment strategy takes advantage of the abrupt distal fall-off a proton beam. By
detecting the distal falloff of a proton beam in vivo, we eliminate the need for the
large distal margin and allow treatment with a highly conformal anterior proton
beam.

The system may also benefit future spot scanning and intensity-

modulated proton therapy techniques, which provide further dose conformality to
reduce normal tissue toxicity.
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Chapter 3: Detection of an anterior proton beam for range
determination
3.1 Introduction
Specific Aim 1: Develop an in vivo proton beam detection device located
within a rectal balloon.
Working hypothesis: An in vivo proton beam detection device located within a
rectal balloon can detect the distal fall-off of a proton beam within 2 mm (95%
confidence interval).
The first part of our detection system includes the endorectal balloon,
scintillating solution, and photon detection system.

With this system, if the

anterior proton beam over-shoots through the prostate, a portion of the proton
energy will be absorbed by the liquid scintillator, which tightly wraps around the
anterior rectal wall and produces light emission within the scintillation liquid. The
light produced can be captured and transmitted to the photo detector using a
fiber optic light guide. The emitted light will be transmitted to a photodetector, at
which the light signal will be converted into electric signal. If the proton beam
range is too short, the proton beam will not penetrate the rectal balloon,
therefore, there will be no signal detected by the system.
This chapter will begin with a description of scinitillation liquids
emphasizing the scintillating fluid that was selected for this work, light capture
with our chosen fiber, and photodection with our photodiode module.

Then

methods to verify dose rate and spatial invariace with photons, the relation of
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anterior beam SOBP depth and photocurrent collected, and estimation of our
technique to register the prostate-rectal inferface using patient CT data, will be
described. The results of these experiments will then be presented, followed by
a discussion of study limitations, scintillation dosimetry, alternate range
verification techiques, and scintillation quenching. We will conclude this chapter
by evaluating our working hypothesis for specific aim 1.

3.2 Materials and methods
3.2.1 Light emission with scintillation
Scintillators are materials that exhibit luminescence when exposed to
ionizing radiation (79).

The ideal scintillator should convert energy to light

linearly and with high efficiency, should be transparent to its emission spectra,
emit scintillation photons promptly, and have a refractive index close to glass for
good optical coupling with a light guide or photocathode window (80). There are
three types of luminescence: prompt fluorescence, phosphorescence, and
delayed fluorescence. Of the three types, prompt fluorescence has the shortest
decay time of 10-9 to 10-7 seconds. The latter two types exhibit longer decay
times of 10-3 to 102 seconds. In the case of pulse mode photodetection, prompt
fluorescence is the decay mode of use and delayed fluorescence and
phosphorescence are considered extraneous noise. In the case of current mode
photodetection, long decay luminescence is proportional to incident ionizing
radiation and therefore a useful fraction of the signal, however background noise
must be removed between each measurement to remove residual luminescence
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or wait a sufficiently long time to ensure the majority of trapped excitons
decay(80).
While there are several forms of scintillators including inorganic crystals,
plastic-based organic scintillators, and other potential detectors such as metal
oxide semiconductor field effect transistors (MOSFET’s) and thermoluminescent
dosimeters (TLD’s), liquid scintillator was selected for several reasons.

The

detector needed to be inserted either inside or on the rectal balloon, which
prohibited the use of large solid detectors. The detector had to conform to the
shape of the rectal balloon and the interface of the prostate and rectum. The
detector had to be sensitive in the SOBP region of the proton beam in real time
as the patient is treated. The real-time measurement requirement eliminated the
use of TLD or film since these have to be removed to process the dose
measurement (81). The use of scintillating fibers (82-85) or MOSFET’s (86-88)
for range determination was possible, however, these measured ionizing
radiation over a small volume and are therefore only sensitive in the fall-off
region of the proton beam. All treatments required a treatment margin, so these
detectors would only be useful for initial daily set-up. The last reason to use
liquid scintillation over other detectors was its relative insensitivity to radiation
damage. The detector remained in the beam for the entire treatment and was
resistant to exposures as high as 105 Gy (80). This radiation resistance enabled
the re-use of the liquid resulting in substantially lower cost if the technique was
used for daily fractionated radiation treatments.
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For these reasons, liquid scintillator was selected as our radiation detector
for range determination during treatment.

The fluorescence process of the

organic scintillators occurred in conjugated, aromatic molecules with rich πelectron structures. Fluorescence occurred when valence electrons are excited
by ionizing radiation into their singlet energy states (Figure 13). These molecules
then lost energy in the form of vibration and internal conversion before decaying
back to ground from the S1 state with the emission of a scintillation photon within
nanoseconds.

Some excited valence electrons transitioned to triplet states

through inter-system crossing and decayed to ground state by phosphorescence
in milliseconds and at a longer wavelength. From the T1 state, some electrons
were re-excited to the S1 state and decay by delayed fluorescence. Because all
excited electrons decayed to S1 or T1 before luminescing, the overlap of
absorption and emission spectra in scintillators was minimal resulting in very little
self-absorption (80).
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Figure 13: Diagram of the scintillation process (79)
The BC-531 liquid scintillation solution was selected (Saint Gobain
Crystals, Newbury, OH) for this experiment. The primary reason for the choice
was the solvent that is used in this solution, linear alkyl benzene. Most organic
solvents used in commercially available scintillating solutions were highly toxic
and

carcinogenic

such

as

benzene,

toluene,

xylene,

cumene,

and

pseudocumene. Linear alkyl benzene was a bound form of benzene that was
considerably less toxic that other solvents. It was also safe to use with most
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solid commercial plastics. Its National Fire Protection Agency (NFPA) health
hazard classification was level 1 and its Hazardous Materials Identification
System (HMIS) health hazard classification was level 1. These classifications
indicated a slight risk for temporary injury from exposure. It was not listed as an
acute or chronic health hazard by state and federal regulation. Exposure may
cause slight irritation of the eyes, skin, or lungs. Ingestion may cause diarrhea,
nausea, or gastrointestinal upset. Considering the stated toxicity of the solution,
our physicians were comfortable using this technique with appropriate
prophylactic measures such as use of a secondary condom around the balloon
and the use of gloves when handling the solution.
Although safety and reactivity with plastics were the primary factors for
determining the proper solution for our project, the other properties of the BC-531
solution also matched the stated aims of our project.

The scintillator output

efficiency was 59% of anthracene, which is comparable to other commercially
available solutions from Saint Gobain Crystals.

Its emission spectrum was

peaked in the visible blue region (Figure 14).

The refractive index of the

solution was 1.47 which is very close to the refractive index of glass (1.5).
Matching these indexes was important for proper optical coupling between the
scintillator, light guide, and photodetector. The solution’s electron density is 2.93
X 1023, per cubic centimeter which was slightly lower but comparable to that of
water. This was ideal because the proton dose and range may be simulated with
a water-filled balloon, and a large difference in electron density could have
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modified the proton’s dose and range in the balloon from the predicted values at
treatment simulation.

Figure 14: Emission spectra of liquid scintillating solution BC-531.

3.2.2 Light capture with fiber optics
In order to convert collected light into an electronic signal, it was first
captured. To achieve light capture in our detector, a single fiber optic cable was
fit through a commercial balloon stem (Radiadyne®, Houston, TX). Water-filled
rectal balloons were used in proton radiation therapy in our clinic as prostate
immobilization devices. Initial studies of patients using water-filled balloons and
receiving repeat CT imaging confirmed the reproducibility of the shape and
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volume of the balloon on subsequent treatment fractions as well as the durability
of the device in routine daily use (89). 35 patients were analyzed with a total of
105 repeat CTs during treatment. The planning CT was registered to each repeat
CT using an in-house developed 3D image registration method. The one
standard deviations (1SD) and (mean; range) are 1.1 mm (1.1; -1.0 to 3.0 mm) in
anterior-posterior (AP), 1.3 mm (-0.8; -3.4 to 2.0mm) in superior-inferior (SI), and
0.5mm (-0.1; -0.1 to 1.0mm) in right-left (RL) directions respectively. The balloon
was expected to maintain its immobilization function when water was replaced by
scintillation liquid.
Light was emitted isotropically when ionizing radiation excited electrons
within the scintillating solution. The fiber was positioned such that it faced the
anterior rectal balloon wall and the majority of the light emission. A small fraction
of the emitted light was incident on the face of the fiber, and this fraction was
approximately the surface area of the fiber divided by the surface area of a
sphere, 4πr2, where r was the distance from the emitted light to the fiber face. A
small portion of the incident light on the fiber face was reflected back into the
solution. The fraction of light polarized perpendicular to the plane of incidence,
Rs, and inside the plane of incidence, Rp, were calculated with Snell’s Law
(Equation 1) and Fresnel’s equations (Equation 2) as a function of the solution
refractive index (n1), fiber core refractive index (n2), angle of incidence (θi), and
angle of transmittance (θt) (90).
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sin θ1 v1 n2
=
=
sin θ 2 v 2 n1
Equation 1: Snell’s law
2

2

2

2

⎡ n1 cos θ i − n 2 cos θ t ⎤
⎡ sin(θ t − θ i ) ⎤
RS = ⎢
=
⎢
⎥
⎥
⎣ n1 cos θ i + n2 cos θ t ⎦
⎣ sin(θ t + θ i ) ⎦

⎡ n1 cos θ t − n2 cos θ i ⎤
⎡ tan(θ t − θ i ) ⎤
RP = ⎢
=
⎢
⎥
⎥
⎣ n1 cos θ t + n 2 cos θ i ⎦
⎣ tan(θ t + θ i ) ⎦
Equation 2: Fresnel’s equations

Once incident photons were transmitted and refracted, they encountered
the normal surface of the cladding with an angle greater than the critical angle
(Equation 3) for total internal reflection (Figure 15). This angle was set by the
ratio of the indexes of the fiber core and cladding. Those photons incident to the
cladding at acute angles were partially transmitted through the cladding and the
reflection portion quickly fell to zero after several reflections. The net result of
these two interfaces (solution/core and core/cladding) was that photons emitted
within an acceptance cone were incident to the solution-core interface acutely for
transmittance and the core-cladding interface obtusely for reflection to propagate
the fiber length and reach the photodetector. The half-angle of this acceptance
cone is illustrated in figure 3 and expressed in equation 4 (90).
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θ crit = sin −1 (

n2
)
n1

Equation 3: Critical angle for total internal reflectance

Figure 15: Internal reflection of a captured photon
(www.edmundoptics.com)
2

sin θ HA =

n1 − n2

2

n0

Equation 4: Half-angle of acceptance in a fiber optic cable
Considering the previous conditions for light collection within our fiber, a
step-indexed, multimode, optical grade fiber from Edmund Optics (Barrington, NJ)
was selected. This fiber had a large difference in the refractive index of the core
(1.492) and cladding (1.402) for a large acceptance cone (half-angle: 30.5o in air).
The calculated critical angle for internal reflection was 20o and the corresponding
half-angle of acceptance in the solution was 20.3o for meridional rays, or rays
that passed through the central axis of the fiber. The half-angle of the fiber was
slightly larger than this value if skew rays, or rays that are internally reflected but
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do not cross the fiber axis, are considered. The reflection coefficients calculated
with equation 2 are displayed in figure 16 as a function of angle of incidence.
Since the refractive index of the solution and core were similar, this value was
close to zero and nearly all incident acutely angled photons were accepted.

Reflection Coefficient of Scintillation Light Incident
on a Fiber Face
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Figure 16: Reflection coefficients of photons emitted inside the solution
incident on the fiber face
This particular fiber was the largest diameter fiber (2 mm) offered by this
vendor with a protective plastic sheath. Although larger fibers could potentially
increase the fraction of light captured, they required a larger bend radius to avoid
damage (Figure 17). The minimum bending radius for these fibers was 25 times
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their outer diameter, slightly greater than 5 cm. For the fiber to face the anterior
rectal wall, it must bend nearly 90 degrees in the distance from the balloon base
to the middle of the stem. The use of the 2mm fiber was the limit that we can use
for controlled in vitro purposes. For insertion into a patient, our detector would
have to utilize a smaller fiber to ensure the fiber was not damaged during the
insertion process. Bending the fiber did have some positive benefit. When the
fiber was bent as shown in figure 17, the angle of incidence along the outer
diameter was decreased, resulting in a rejection of modes with characteristic
angles close to the critical angle of the fiber and a narrowing of the collection
cone (90). Normally this would be detrimental to light collection and users of the
detector would have to ensure that the fiber remains straight during use.
Bending the fiber acutely, as in our detection volume, automatically rejected the
highest order modes. This ensures that subsequent bends down the fiber did not
affect the light output and that our light collection was consistent. Even though
fiber bending decreased total light collection, it ultimately increased the
robustness of our detector.

47

r

Figure 17: Bend radius of a fiber optic cable
Since the dose deposition of a flat anterior proton beam inside our solution
and the corresponding light output was known along with the light collection of a
fiber facing the anterior balloon surface, we could mathematically express the
light collection within our fiber (Equation 5).
k

Light ( d ) = μ sc in ∫ ε Sc in Dose(d , x) *
0

π * rfiber 2
4π ( k − x) C( k − x ) 2 → r 2
2

* ( k − x) tan θ HA ) 2 dx

Equation 5: Expression for two-dimensional light collection
The total light emitted by our solution was proportional to the energy
deposited [Joules] and scintillation efficiency [~ constant 3-5 %](79). Thus, light
emitted was the product of dose in units of the scintillation efficiency [~ 3-5 %],
Grey [Joules/kg], the density of the solution [kg/cc], and volume [cc]. Not all
emitted light was collected.

Only the light within the collection cone was
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accepted into the fiber. The volume of the cone subtended by the beam was the
product of the distance of the fiber to the beam, k – x, and the tangent of the
fiber’s half-angle of acceptance squared, multiplied the thickness of the cone, dx
(Figure 18). The portion of light incident on the fiber face from an isotropically
emitting source was inversely proportional to the distance to the fiber face, ~ (k-x),
squared. A term was included in the denominator to scale (k-x) to the average
radial distance on the cone at the point, (k-x). This value was approximately 1.08.
Therefore, light collected was independent of the distance from the fiber face to
the anterior surface of the detector, k. The remaining terms were product of
constants, dose (x), and dx. Thus for a large flat one-dimensional beam, light
collected in our fiber was proportional to the integrated depth dose within the
detector.

For a uniformly distributed dose, such as the proton SOBP, light

collected was linear with depth of the beam within the detector.
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Figure 18 Expression for light collection of a fiber facing the anterior
detector surface
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3.2.3 Light conversion to current with photodetection
Though, there were several options to choose from, to detect scintillation
light, a photodiode was selected for several reasons. Photodiodes were cheaper
than alternatives such as photomultiplier tubes (PMT) or charge-couple device
(CCD) cameras.

They were also insensitive to magnetic fields. This was

extremely important if the detector was inside the treatment room during
measurement. They typically had a greater fractional yield of photoelectrons per
incident photon, or quantum efficiency, than PMT’s. They were mechanically
rugged and required only battery power for operation (80). These features were
very important if the device was used daily during a patient’s fractionated
treatment. PMT’s required a stable high voltage source because the detector’s
gain was highly dependent upon the applied voltage to the dynode structures
during electron multiplication (Hamamatsu PMT handbook).

The supporting

electronics for PMT operation were bulky and non-ideal for clinical use. CCD
cameras required external cooling to achieve a sufficient signal-to-noise ratio for
precise scintillation detection.

The cooling process can take more than 30

minutes, which may be impractical for repeated use.
Photodiodes ideally generated current proportional to the light incident on
their photocathode.

As scintillation light reached the photocathode of the

photodiode, valence electrons originating from the doped impurities in the crystal
lattice were excited from the valance band into the conduction band (80). The
energy difference between these bands was called the band gap energy and was
1-2 eV for silicon photodiodes. The typical energy of an incident scintillation
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photon was typically 3-4 eV, sufficient to generate electron-hole pairs in the
cathode. The bias voltage then forced current across the depletion region to the
diode’s anode. This current could then be measured with a digital volt meter or
oscilloscope across a load resistor or directly with a current measurement tool
such as an electrometer.
We chose the DET36A biased detector (Thorlabs, Newton, New Jersey)
for our measurements. This detector was a silicon PIN photodiode that had a 3.6
mm by 3.6 mm active area sensitive to photons from 350 to 1100 nm (Figure 19).
The specified dark current was 0.35 nA with a 10V bias voltage. The internal
electronics was enclosed in rugged aluminum housing and included a BNC
output, a battery check switch, and a threaded optical coupler for adapting
lenses, filters, or SMA/FC fiber adapters. The output of the detector was linear
with incident light intensity up to 1 mA output. The lifetime of the included 12 V
bias battery was stated 40 hours at 1 mA output current.
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Figure 19: Spectral response of the DET36A module (www.thorlabs.com).
An SMA adapter was threaded into our detector. The SMA connector was
then drilled to 2 mm in diameter to match the diameter of the selected optical
fiber (Figure 20 top). The fiber was then glued into the connector and its face
was polished incrementally with 800 to 2000 grade abrasive paper to provide
quality optical coupling to the surface of the photodiode. After threading the fiber
to the surface of the diode, black electric tape was applied over the connector
and thread to maintain the coupling. An additional layer of aluminum foil and
electric tape was applied to shield the residual light leakage.
The photocurrent generated by our detector was measured with a Keithley
602 electrometer (Keithley Instruments, Inc, Cleveland, Ohio). To connect the
detector to the electrometer, a male/male BNC adapter and female BNC to a 2
lug triaxial male adapter was used to mate the female BNC output of the detector
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to the female triaxial input of the electrometer (Figure 20 middle).

The

electrometer was set to current mode in nanoamperes (10-9 A) for all
measurements.
To generate a digital signal for data analysis, the analog output on the rear
side of the electrometer was connected to an analog-to-digital converter (ADC).
The analog output of the electrometer provided voltage representing the selected
scale of the front of the instrument, The DATAQ DI-158 programmable ADC was
selected for USB interface with our computer. This four-channel ADC had 12-bit
resolution over +/- 64 Volts, an internal gain range from 20 to 29, and a maximum
sampling frequency of 14.4 kHz. Based on preliminary photon measurements
with our detector system, photocurrent from 0 to nearly 1 nA was observed at
maximum dose rate with an open field. Therefore the internal gain was set to 64
to best match the estimated current range and to optimize the 12-bit resolution
(+/- 2048 steps) of the ADC for approximately 0.488 picoampere measurement
precision.
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Figure 20: Photodiode module (top), electrometer (middle), and analog-todigital converter (bottom) for converting emitted light into a digital signal
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Operation of some of the programmable features on the ADC required the
use of Dataq’s WinDAQ software (DATAQ Instruments, Inc., Akron, OH). Use of
the free version of the software throttled our sampling frequency to 240 Hz;
however the software had an option to average the sampled data (at 14.4 kHz) to
the 240 display frequency. This significantly reduced variation of the background
noise, and increased the signal-to-noise ratio for the detector.

The vendor

software also provided recording features and data processing options. However,
we interfaced both devices with LABVIEW (National Instruments, Austin, TX) for
future integration of the detector with the dual wedge range shifter.
With the WinDAQ software operating in the background, the LABVIEW
drivers provided by the vendor passed the scaled data to our LABVIEW virtual
instrument (Figure 21). The LABVIEW virtual instrument had an on/off switch,
channel selector, numerical data register and graphical data real-time display.
The virtual instrument used the ActiveX controls of the driver to initialize the ADC,
select the measurement channels, and obtain the scaled data from WINDAQ.
The program used a timed loop and shift register to retrieve the data, display the
data on the front panel, and generate an array with the measurements. The
program then exported the array in a tab-delimited spreadsheet for subsequent
analysis.
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Figure 21: Labview virtual instrument for our detector.

3.2.4 Experiment methodolgy
Before beginning the experiments, 60 mL of liguid scintillation solution was
inserted into commercially available endorectal balloons to test the compatibility
of the balloon material with the chosen scintillation solution. The first balloon
selected, a latex balloon from MEDRAD (MEDRAD, Inc., Pittsburgh, PA), was
damaged after the solution was left several days in the balloon.

When the

balloon was removed from the experimental phantom, the stem ripped from the
balloon at the base. The same test was then attempted with the Radiadyne
(RadiaDyne, LLC, Houston TX) balloon made of a plastic material. After two
weeks of holding the solution, the balloon maintained its shape and structural
integrity.
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The preliminary measurements were made in a light shielded IMRT film
phantom (Figure 22). A 2 mm fiber was inserted into the vial straight down from
the top of the volume, collecting light from most of the detector volume. External
fiducials were used to mark align the center of the detector volume and the
treatment isocenter for the first measurements. After the fiducials were affixed to
the phantom and the vial was in its permanent position, the phantom was imaged
with a CT scanner. Using the CT data, the dose delivered to the vial during the
measurements was calculated and compared with the generated photocurrent.

Figure 22: IMRT film phantom for preliminary measurements
For the first set of measurements, the 10 X 10 cm2 open field generated
photocurrent was measured with dose rates of 100, 200, 400, and 600 monitor
units per minute for 50, 100, 200, and 300 monitor units respectively. The realtime current generated by these measurements was background subtracted and
correlated with the dose rate delivered to the solution with the Pearson
parametric correlation.
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Once

dose

linearity

was

established,

the

next

set

of

photon

measurements investigated the sensitivity of light collection as a function of
position within our detector. The MLC shaper software (Varian Medical, Palo
Alto, CA) was used to vary the position of the beam in real time. This software
conveniently modified the multi-leaf collimator control points within the Pinnacle
treatment planning system (Royal Philips Electronics, Amsterdam, The
Netherlands). Using the preliminary detector prototype and IMRT film phantom,
we measured the photocurrent with a 3 mm wide MLC window that traveled at a
constant rate across the field width from the anterior to posterior portions of the
phantom (Figure 23). Figure 23, illustrated the 3mm sliding window segment
delivered to the test phantom in the Pinnacle treatment planning system with
isodose lines ranging from 60% (red) to 10% (white) of the max point dose within
the phantom. The length as well as the width of the sliding window was varied to
investigate these factor’s effects on the measured current. To investigate the
relation of light collection as a function of distance from the fiber face, the
collimator was rotated 90 degrees and a 4 cm by 3 mm sliding MLC window was
delivered superiorly from the bottom of the vial (top of figure) past the face of the
fiber. These measurements suggested that redesign of the detector with the
fiber facing the anterior detector surface may result in superior performance.
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Figure 23: MLC sliding window in the test phantom
After the previous measurements, a second detector was fabricated with
the fiber facing the anterior detector wall. The Radiadyne outer balloon was
removed and a hole was drilled through the stem at 45 degrees. A light-tinted
glass vial of comparable volume and length to the commercial balloon was used
as a surrogate in all of the measurements. The plastic cap of this vial was drilled
with holes to the exact dimensions of the balloon stem and fiber to ensure that
the vial would remain liquid tight during our experiments. After threading the
balloon stem and fiber through the plastic cap, the fiber was inserted into the 45
degree hole drilled into the stem of the balloon and fixed into position with Krazy
glue. The holes at the base of the vial cap were also coated with Krazy glue to
close the residual gap between the fiber, stem, and cap. The vial was then filled
with 60 mL of liquid scintillator. The vial remained closed for the duration of all
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experiments.

The position of the stem and fiber within the balloon was

subsequently verified by CT (Figure 25).
A custom-made deformable phantom simulating a male pelvis, was used
to measure radiation doses in the (simulated) prostate target and anterior rectal
wall. The phantom, as shown in Figure 24, was made of tissue substitute
materials by blending epoxy resins, urethanes, water based polymers and other
proprietary materials (CIRS, Inc., Norfolk, VA). The phantom had an opening for
inserting the rectal balloon and scintillation detectors designed in this study.
When the balloon was inflated, the rectum displaced the prostate target
anteriorely, which simulated the conditions of rectal filling in a patient treatment.
The deformable phantom was used to simulate a patient treatment and test our
scintillation detectors system before applying this technique to real patients.

Figure 24: A custom-built deformable pelvic phantom
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Figure 25: Light vial with machined stem and fiber inserted into our
anthropomorphic phantom
After construction of the light detection portion of the beam positioning
device, the precision of the detector was measured. To measure the precision, a
measurement was performed with a single proton beam incident upon a water
phantom that holds the scintillation detector (Figure 26).

The phantom was

irradiated at the University of Texas M D Anderson Proton Therapy Center in
Houston, TX on the G1 rotatable beam gantry. The beam delivered 200 MU to a
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depth of 17.7 cm with a 10 cm square field size and 10 cm SOBP at
approximately 270 cm SAD in physics mode.
detector interface was 11.7 cm.

Physical depth to the anterior

A variable thickness of known attenuator

(polystyrene slabs) was repeatedly moved into the distal fall-off of the beam in
order to determine the detection threshold as a function of beam depth. The
initial build-up thickness was 6 cm. The current was then measured with build-up
of 5.5 cm to 6.5 cm in 1 mm increments.

We then measured with build-up

thickness of 5 cm, 4.5 cm, and 4 cm. Pulses were background subtracted and
integrated over the 200 MU delivered to generate the photocurrent as a function
of SOBP depth into the detector. Since the radiological depth to the detector
surface was unknown, the known relation for light collection was exploited to
determine the point where the SOBP reaches the detector. Since the relation is
linear and builds in the fall-off region, a bilinear fit of the SOBP and fall-off
portions of the relations was used to find the point where the relation diverges.
The origin was then reset to this point.
The reproducibility of the light output as a function of beam position
determined the uncertainty of the light collection device.

Since treatment in

physics mode resulted in uneven proton spills, each spill was normalized to the
number of monitor units delivered. The standard deviation of these normalized
pulses was then measured for each SOBP position and the coefficient of
variation at each point was calculated. For illustration purposes the error bars on
the SOBP depth versus photocurrent reflected the coefficient of variation of the
proton spills for each point. Using these error bars and the measured gradient of
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the relation when the SOBP is inside the detector, the spatial resolution of our
technique was determined assuming a single proton spill was used to determine
depth.

Figure 26: Experimental apparatus for measuring the photocurrent as a
function of SOBP depth
Although phantom measurements provided an estimation of the device’s
precision as a function of SOBP depth within the detector, it did not take into
account the variation of dose and subsequent light emitted as the balloon and
target organs deform in shape. For this experiment, the worst case scenario was
assumed, that the scintillated light emitted and captured is proportional to the

64

mean dose in the detector volume. Estimation of in vivo uncertainty of the light
output of our scintillator is the worst case scenario because light collection was
specific to the depth of the proton beam within the detector. The prototype was
theoretically insensitive to some deformation as discussed in figure 18. .
Eight prostate cancer patients enrolled in an IRB-approved protocol
contributed 8 reference and 19 total daily CT image sets for this study. Each CT
data set was imported into the Pinnacle treatment planning software for
dosimetric calculations. A single beam from the lateral direction was created for
delivery of the sliding MLC window. To create the aperture for the window, a
2mm diameter circular ROI was created inside the anterior edge of the rectum on
each axial slice. This ROI was then expanded anteriorely by 3 mm. The final
ROI was generated by subtracting the anterior point ROI from the expanded,
leaving a 3mm wide ROI tightly abutting the anterior rectal wall.

The MLC

segment was then created by blocking the beam to this ROI (Figure 27). To
simulate the sliding of this segment in Pinnacle, 10 additional beams were
generated from the original beam with an isocenter displaced anteriorly and
posteriorly in 1mm increments from -5mm to 5 mm.
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Figure 27: Beam-eye-view of the MLC sliding window segments
Each segment was set to deliver 500 MU in order to generate the required
dose display precision in Pinnacle.
resolution.

The dose grid was set at 3 millimeter

The mean rectal dose delivered to the entire rectum was then

calculated in Pinnacle. The mean rectal dose of each segment was then plotted
against the beam position to generate the reference dose-position relationship
(Figure 28) on the patient’s reference CT.
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Rectal Dose vs MLC Segment Distance from the ARW
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Figure 28: Mean rectal dose as a function of segment distance from the
ARW
This relation was then compared to similar relations calculated on the
patient’s daily CT image sets for simulated device registration based on mean
rectal dose and thus light emitted within the balloon.

These daily graphs were

then manual shifted to match the reference relationship and obtain the daily
corrective shift to align the treatment at the anterior rectal wall (Figure 29). In the
cases were the slopes were significantly different, the relations were matched at
the origin on the reference CT when possible.
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Figure 29: Manual registration of dose-position relation for alignment
The same CT image sets were then imported in our in-house CT
registration software, Computer-aided Targeting (CAT) (59, 91).

A one-

dimensional alignment of the anterior rectal wall was manually determined to
validate the dosimetry method, as shown in Figure 30. In cases where the rectal
position rotated, alignment was attempted at the anterior rectal wall near the
center slice of the prostate.
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Figure 30: CT registration of ARW in CAT
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3.3 Results
3.3.1 Preliminary photon measurements
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Figure 31: Photocurrent as a function of open-field dose rate
The results of the open-field dose rate dependence were illustrated in
figure 31. The ADC for these measurements was set to 60 Hz and internal gain
set to one. This was the reason the data appears to have low resolution (both
axis). There were also issues with the LABVIEW drivers incorrectly fetching the
scaled data, so the effective sampling rate was slightly less than 60 Hz. These
issues were resolved in later experiments by changing the baud rate of the ADC,
and fully leveraging the dynamic range of the ADC by setting the gain. The
periodic signal variances shown in the figures were specific to one linac used in
measurement. The magnitude of the variance illustrated in figure appeared to be
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dependent on the dose rate; however it did not appear to be linearly correlated.
The background was very stable, approximately 183 picoamperes. Variation of
the 100 and 200 MU/min rate appeared to be similar, as do the 400 and 600
MU/min rates.

These measurements were then background subtracted and

averaged to investigate the linearity of signal output as a function of dose rate.
Correlation of detected signal with open field dose rate
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Figure 32: Correlation of mean photocurrent with the open field dose rate
Figure 32 illustrated the average background subtracted photocurrent as a
function of dose rate. The photocurrent generated was slightly greater than 1
picoampere per MU/min. The photocurrent was highly correlated with dose rate
(p <0.001). The standard deviation, as shown by the error bars in the figure 32
and displayed in Table 1, appeared to be similar in magnitude for the 100 and
200 MU/min dose rates and the 400 and 600 MU/min dose rates.
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Dose
Rate
[MU/min]
100
200
400
600

Average
signal [pA]
102.70
209.86
410.32
616.86

Standard
Deviation
11.78
13.17
23.54
20.96

Table 1: Photocurrent as a function of open-field dose rate
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Figure 33: Photocurrent generated by reduced size sliding windows
Figure 33 showed the current generated by a 4cm by 10cm MLC window
as it traveled across the beam aperature. The resulting dose was delivered
anteriorely through the IMRT film phantom and the detector volume.

The

measured current peaks as the window reached the fiber axis. We compared the
4 cm X 10 cm X 3 mm window with a 4 cm X 10 cm X 5 mm window and 2 cm X
10 cm X 5 mm window. As we anticipated, increasing the width of the gap
increased our signal and reduction of the window length decreased the dose and
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signal. Reduction of the window length was clearly the dominant of the two
factors. If this technique was implemented for IMRT patient set-up, window size
reduction could potentially decrease extraneous patient dose.
Sliding Window with one centimeter travel length
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Figure 34: Photocurrent generated from 4X10 cm MLC window with 1 cm
travel length
Figure 34 illustrated a 4 cm X 10 cm X 3 mm window with a one
centimeter travel length starting five millimeters inside the detector and traveling
to the outside of the detector wall.

This particular technique could be used

localize patients with minimal dose before the treatment.

The short buildup

region in the first 3 seconds showed the MLCs opening to their 3 mm width. The
dose steadily decreased as the window moves away from the position of peak
sensitivity in the center of the volume. This figure was used again to correlate
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the photocurrent generated as a function of sliding window delivered dose as
estimated in the Pinnacle treatment planning system documented later in this
chapter.
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Figure 35: Photocurrent generated from a MLC window traveling up the
detector volume
Figure 35 illustrated the photocurrent generated as the window travels
towards the fiber face from the bottom of the detection volume. The width of the
photon beam penumbra was fairly large, approximately 2 cm, which led to an
initial buildup of current signal. Once the dose delivered by the window was
completely inside the vial, the output current signal was constant for both dose
rates until the window reaches and passes the face of the fiber.

This

measurement validated Equation 5. The increased capture fraction of photons
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emitted from any point within the volume by the fiber face was canceled by the
decreased cone volume as the window reached the detector.

3.3.2 Anterior Proton Beam Simulation
Figure 36 illustrated the detection of a single proton spill when the anterior
detector interface is mid-way through the proton SOBP (5 cm). The measured
spill was consistent with the known properties of of the Proton Therapy Center
synchrotron. A proton spill from the synchrotron was approximately 0.5 seconds
in duration. Each spill was approximately 2 seconds apart. During each spill, the
range modulator generated a uniform dose delivery to the entire SOPB.

To

obtain a uniform dose, the majority of the peaks were weighted near the distal
end of the SOBP. The modulator wheel rotated at approximately 6.6 Hz. For
each rotation, the wheel completed three modulation cycles, in and out of the
detector at the distal end of the SOBP. Based on these properties, we expected
our signal to build as the beam moved into the detector and decrease when the
beam was retracted. Therefore, our signal had a frequency of 20 Hz within the
spill. We observed exactly 10 peaks in the signal with each spill as shown in
figure 36.
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Figure 36: Proton spill with the detector anterior surface in the middle of
the proton SOBP
Figure 37 illustrated a series of spills at a position mid-SOBP compared to
a series of spills near the therapeutic range. Even with the SOBP well within the
detector, the peak signal was not consistent. The cause of these discrepancies
was the delivery of the beam in physics mode. When using physics mode, the
tolerances of the gantry were relaxed to lower the cost of running the beam. This
led to a slight variation in the initial beam energy or loose windowing of the
modulator wheel. Either one of these potential effects could cause a variation in
the observed range (signal peak) mid-spill. The figure also illustrated that this
variation is much more apparent at the distal end of the SOBP (therapeutic
range). Theoretically, some range modulation peaks should reach the detector
and others should fall short.
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Figure 37: Comparison of proton spills mid-SOBP with spills at therapeutic
range
Figure 38 showed the relationship of integrated photocurrent over the 200
MU delivery as a function of SOBP depth within the detector.

The relation

showed gradual signal buildup in the distal falloff region and linear output in the
SOBP region as predicted in Figure 18. Since the relationship diverged from
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linearity at therapeutic depth, the measurement origin was reset with a bilinear
fitting of the signal with the distal falloff and dose within the SOBP. This fit was
rounded to the nearest millimeter.

The fit predicted the SOBP reached the

detector approximately 2 mm further than the measured 11.7 cm inside the
phantom to the anterior detector wall. This adjustment was reasonable because
the tissue-equivalent material had a slightly higher stopping power than water.
The standard deviation of the spills was 19.5% at our original origin (-2 mm
position) and decreased to approximately 11% in the saturation region.

The

linear fit of the measured data in the SOBP region yielded a gradient of 1.0183
nC/cm. Pulse variation was 17% or 0.052 nC at 2 mm depth corresponding
approximately 0.51 mm considering the signal gradient in the SOBP. If in vitro
detector uncertainty was the only source of uncertainty, our margin to treat with
95% confidence would be approximately 1 millimeter.
Detector signal as a function of SOBP depth
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Figure 38: Photocurrent generated as a function of SOBP depth
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3.3.3 In Vivo treatment Uncertainty
Figure 39 illustrated the agreement between the one-dimensional
registration based on the rectal dose/ light emitted and the one-dimensional
manual registration of the anterior rectal wall using the CAT, CT-to-CT
registration software. The two values were highly correlated and the standard
deviation of the difference between the two alignment techniques was 1.1
millimeters, and the average magnitude of differences was 0.76 millimeters.
Comparison of MLC Sliding Window Alignment with Manual
Registration
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Figure 39: The corrective shifts generated from the sliding MLC technique
compared with manual registration
To validate the use of mean dose as a surrogate for light output and
photocurrent signal, we compared the current signal in picoamperes with the
simulated delivery of the 4 cm sliding window as calculated in the Pinnacle
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treatment planning system (Figure 40). The original measurement was obtained
from Figure 34. The series in blue was the measured current signal with delivery
of the 4 cm by 10 cm by 3 mm sliding window. We sampled Figure 34 into 10
equidistant measurements for comparison with the treatment planning dose.
Mean dose calculated from the treatment planning system was highly correlated
with the measured photocurrent (p<0.01)

Figure 40: The measured current signal [pA] and mean dose [cGy] as a
function of window position.
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3.4 Discussion
3.4.1 Summary and discussion of results and aim
In summary, we built a device for detecting the fall-off of an anterior proton
beam to reduce range uncertainty during treatment. This device consisted of a
liquid scintillation filled rectal balloon with a single fiber machined through the
stem at an angle slightly greater than 45 degrees. When the fall-off reached the
anterior balloon surface, scintillation light was emitted isotropically in proportion
to the dose and corresponding energy deposited within the fiber’s collection cone.
This light was collected by the fiber and guided to a silicon photodiode. The
diode generated current in proportion to the incident light.

This current was

measured by an electrometer and converted to a digital signal for computer
analysis.
Our aim for this chapter was to design an in vivo proton beam detection
device located within a rectal balloon that could detect the distal fall-off of a
proton beam within 2 mm (95% confidence interval). To evaluate our design, we
measured the photocurrent produced by an anterior proton beam in our
anthropomorphic phantom and detector prototype as a function of SOBP depth
from the anterior interface of the detector. By investigating the signal gradient
and variation of the individual proton spills, we approximated the uncertainty of
positioning the patient with each proton spill in real-time. The 95 % confidence
interval at 2 millimeters from our corrected interface was approximately 1 mm.
We wanted to extrapolate this technique and corresponding uncertainty for use in
a patient. Since the total light output was a function of the energy deposited in
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the scintillator and the rectal volume was nearly constant in patients with
endorectal immobilization, we used mean dose as a surrogate for light output in
the treatment planning system. The relation of beam position with rectal dose
was a function of the distance of the beam from the prostate-rectal interface and
the shape of the balloon. Therefore we simulated set-up with the device by
registering patient’s prostate-rectal interface with an MLC sliding window induced
rectal dose.

We then compared alignment with the mean dose gradient to

manual one-dimensional alignment with CT registration software to isolate output
variation induced from shape deformation of the balloon. The standard deviation
of agreement was 1.1 millimeters.

Assuming that the in vitro and in vivo

uncertainty sources were independent and random, the composite 95 %
confidence interval was approximately 2.4 millimeters in each direction. Thus,
we narrowly missed our aim of 2 millimeter precision. However, considering the
study limitations and the potential for improvement as discussed in the
proceeding sections, our initial 2 millimeter guess was an excellent. If we relax
our 95% confidence criteria to 90%, the interval is exactly 2.0 millimeters.

3.4.2 Design limitations
There were several limitations in design, implementation, and testing of
our device precision.

The first limitation of our device was the use of liquid

scintillation as our radiation detector.

The solution was slightly toxic and

therefore required special handling, storage, and prophylactic safety measures
for use in patients. The solution was also noxious and difficult to clean when spilt.
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Additionally, exposure of the liquid to air resulted in signal quenching, so airtight
storage was necessary to ensure signal integrity.
The second limitation of the detector was the energy-dependent
quenching of the solution in the distal fall-off. Only a small fraction of the energy
deposited within the solution was converted into light. For the ideal scintillator,
the fluorescence yield was proportional to the energy loss as in equation 6.

dE
dL
=S
dX
dx
Equation 6: Ideal scintillator output
In equation 5, the light output of the scintillator per unit pathlength was
proportional to the linear stopping power multiplied by the efficiency of the
scintillator. This relation held for electron energies in excess of 125 keV, but this
threshold was significantly higher for larger charged particles such as protons
(80). To account for LET-dependent quenching from damage molecules in the
solution, an additional term was added to the denominator in Birk’s formula (92)
(Equation 7).

dE
dL
dx
=
dE
dx
1 + kB
dx
S

Equation 7: Birk’s formula for quenched scintillator output
For low LET radiation, this formula reduces to equation 6 and the light
output is directly proportional to the energy deposited in the solution. For high
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LET radiation, scintillation efficiency approached the empirically determined
value, S/kB, where B was the probability of damaging a fluor in the solution and k
was the probability that the damaged molecules will quench the excitons in the
solution.

These terms were unable to completely account for quenching, which

continued to increase with increasing LET of low energy charged particles.. This
additional quenching may have been due to interaction between mutually excited
electrons as the ionization density was increased(93). To account for quenching
that continued to scale with decreasing energy, an additional quadratic term was
added to the denominator in Equation 8.

dL
=
dx

S
1 + kB

dE
dx

dE
⎛ dE ⎞
+ C⎜
⎟
dx
⎝ dx ⎠

2

Equation 8: Birk-Chou model for LET-dependent quenching
The three terms, S, kB, and C were experimentally fit and provide good
agreement with measured values While several authors have recently discussed
liquid scintillation for external beam dosimetry (94, 95), few have modeled proton
quenching in scintillators ((96), Beddar and Siebers 1995) and one author
experimentally determined quenching in BC-531 (97).

Beddar et al. used a

plastic tank and CCD camera system for quality assurance dosimetry of a proton
pencil

beam.

Scintillation

measured

depth

dose

deviated

from

the

measurements made with a parallel plate ionization chamber from three factors,
the focal depth of the lens system, optical blurring, and scintillation quenching.
The absolute efficiency of the scintillator at the Bragg peak of a 120 MeV beam
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was approximately 70%. More troubling for relative dosimetry purposes, was the
observed degradation (widening) of the falloff, however, this was primarily due to
optical blurring and would not be present if the light was collected closer to the
source.
We anticipated a very small deviation (sub-millimeter under-estimation) in
the position of the distal fall-off when the quenched depth dose was integrated
with our detector. This value would be approximately the distance to agreement
(relative) between the quenched depth dose and measured depth dose.
Fortunately, the strongest factor in quenching was the initial proton energy and
depth.

Therefore, most of the deviation would be systematic and could be

mathematically modeled with Monte Carlo (96). Then the predicted range with
our technique could be corrected based on the initial energy of the proton beam
and the measured depth.
Another potential limitation of our design was due to the dependence of
light collection efficiency on the coupling efficiency at each optical interface (98).
Although we do not couple to our scintillator as in scintillating fiber dosimetry, we
can still lose a large amount of light at the coupling of our fiber to the face of the
photodiode. Loss of some of the light at the coupling was not detrimental to our
goals, since we observed signal well above background while still in the fall-off
portion of the beam.

However, we maintained the same coupling at the

photodetector for all of our measurements. The only way to maintain identical
coupling for in vivo application of our device was to use the same exact system
for all measurements.

Reuse of the balloon between patients may not be
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feasible. Therefore, we would re-couple at the diode if the balloon and complete
fiber length were fabricated together or we could apply a fiber adapter at the
base of the balloon and reuse the length of fiber leaving the treatment room. The
variation in the re-coupling with a fiber adapter would be similar to the
measurements of Ayotte et al. (98) who investigated variance in coupling to
scintillating fibers. They reported 10% variance with proper fiber preparation and
consistent procedures. This variance would significantly contribute to the spatial
resolution of our detector and potentially increase the distal margin needed to
ensure treatment confidence.

3.4.3 Study limitations
The first study limitation was the operation of the synchrotron gantry in
physics mode. When in physics mode, the tolerances for proton energy and
range modulator windowing were looser.

Therefore much of the observed

variation in the proton spills may not reflect treatment in clinical mode in an actual
patient. To better estimate the precision of our technique, we should repeat the
experiment by generating a treatment plan in Eclipse and delivering the plan in
clinical mode. We could repeatedly deliver the plan with different amounts of
degrading material in the beam to generate the sensitivity of our detector as a
function of SOBP depth.

Since the measured precision with this technique

should be considerably less, we could still establish feasibility with our previous
measurements.
The second study limitation was the use of photon mean dose in Pinnacle
to estimate the in vivo uncertainty of our device. Mean dose was an excellent
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surrogate for total light emitted inside our balloon and light collected with our
initial prototype design. Our latest prototype was only sensitive to the depth dose
between the fiber and anterior rectal wall. The light collection of our prototype
along with the sharper dose fall-off of the proton beam in the balloon should lead
to a much smaller in vivo detection precision. Since the precision measured was
close to our stated aims, we deferred these measurements to a later date.
The final limitation of our study was the ability of the registered plan to
cover the clinical target volume. Assuming we registered the plan to a point on
the anterior rectal wall, deformation of the target organs, particularly rotation (44),
may move the target slightly out of the treatment field. Use of two fibers, one at
the base of the prostate and one at the apex, could theoretically detect rotation
during treatment.

The precision of each fiber should be identical to our

measurements. Proper range correction to account for a rotation in the target
organs could be challenging.

3.4.4 Alternative range verification techniques
Lu et al (99, 100) has investigated the use of point dosimetry (MOSFETbased) at the anterior rectal wall at MGH for in vivo range verification. This
method exploited the range modulation in the proton SOBP and approximated
the residual range of the proton beam based upon when the Bragg peak reaches
the point detector within the patient. Each point within the Bragg peak had a
unique periodic dose rate was used as a “ruler” for in vivo range verification. The
precision of this technique was dependent upon many factors such as variation
of the spectral fluence at depth caused by heterogeneities in the patient. It was
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also highly dependent upon the temporal resolution of the detector, since their
technique was dependent on reproducing the dose rate at a point with fidelity.
At this point in time, the MGH group does not have the capability to
synchronize their measurements with the range modulator wheel and gantry in
vivo. They have proposed a second method for range verification using only the
dose measured at a point at the anterior rectal wall.

Liquid scinitllator was

selected for this thesis due to its sensitivity in the SOBP region of the beam. The
method that Lu et al proposed artificially created a gradient in the SOBP by
treating with two beams, one with increasing dose in the SOBP and the second
with decreasing dose in the SOBP. The sum of these two beams generated a
uniform dose in the SOBP. They then have an algorithm that reconstructed the
range based on the ratio of the doses delivered to the point by both beams with
approximately millimeter precision.

This method could provide reliable

interfractional correction, however real-time correction would be slightly more
challenging.
Another potential range verification method was PET verification (101104).

When the patient’s tissues are irradiated with protons, positrons were

emitted from activated isotopes e.g.,

11C, 10C, 15O

within the patient. The activity

can then be predicted based on the range of the protons, total dose, dose rate,
and dose distribution within the patient. The positron decay can be measured
either in-room or shortly after therapy by moving the patient into a nearby
imaging suite. The primary limitations of this method for range verification were
the relatively short life-time of the isotope, biological wash-out, and the inherently
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low resolution of the imaging modality. If the method were used for real-time
tracking, i.e. 4DPET, the disadvantages of the modality would be compounded
with the relatively low counting statistics from obtaining images over a very short
duration. While PET verification had the potential to improve proton therapy for
all disease sites, its performance for verification at the anterior rectal wall will not
out-perform direct measurement techniques.

3.5 Specific Aim 1 conclusions
A scintillation filled endorectal balloon was designed for real-time
determination of an anterior proton beam’s range. The goal was 2 millimeter
precision and that goal was nearly met with an estimated 95% confidence
interval of 2.4 millimeters. Given the precision of the initial measurements, use of
this technique for real-time adaptive proton therapy with our technique was
certainly feasible.

The estimated in vitro precision of our technique also

exceeded the measured precision of other range verification techniques and was
simpler to clinically implement.

Further development of this technique was

needed to translate this technology into the clinic.
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Chapter 4: Development of a dual wedge range shifter
4.1 Introduction
Specific Aim 2: Develop a computerized external proton beam range shifter
to modulate proton beam energy/range.
Working hypothesis: An external proton beam range shifter can modulate proton
beam energy/range and localize the distal fall-off of a single anterior proton beam
to the anterior rectal wall within 2 mm (95% confidence interval).
To adapt the incoming beam energy to the daily variation of the rectal wall
position, a range shifter was placed in the beam path between the end of the
proton beam nozzle and the anterior skin surface of the patient, as diagramed in
Fig. 12. The range shifter was a pair of triangularly shaped Lucite attenuators,
one which was fixed and another which was dynamically adjusted. The thickness
of the range shifter was controlled precisely by a stepping motor, which
controlled the horizontal positions of two triangular objects. A thicker range shifter
in the beam path will pulled the distal proton beam edge anteriorely from the
prostate and rectum interface, sparing the rectum from excessive (overshooting)
radiation. A thinner range shifter, on the other hand, increased the proton range
to ensure that the posterior coverage of the prostate target to the adequate
prescribed dose level.

The goal for this chapter was to develop this wedge

shifter based on observation of anatomic deformation of prostate cancer patients
and determine the precision of the range system to degrade the proton’s range
from a calculated value.
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4.2 Methods and materials
4.2.1 Degradation of the beams energy and range
Most proton synchrotrons or cyclotrons employed some method of
reducing the proton’s energy and range by placing attenuating material in the
beam’s path. Inside this material, proton’s lost energy from multiple Columbic
interactions with electrons resulting in a reduction of the proton’s energy and
residual range (105).

Some of the protons interacted with the nuclei in the

attenuating material and deposited most of their energy, resulting in a loss of
proton fluence and dose delivered to the target. Since the energy loss of the
proton per unit pathlength was proportional to the inverse square of its energy,
placing attenuating material upstream from the target substantially reduced the
proton’s range while retaining most of the energy for deposition within the target
(106).
In beam lines that deliver high energy protons, attenuating plates were
used to coarsely step the proton energy to the desired range, as in the Proton
Therapy Center – Houston (107) and the Paul Scherrer Institute in Switzerland
(108). In beam lines for lower energy protons that treat small superficial legions
such as ocular tumors, a wedged attenuator was placed in the beam’s path to
finely degrade the proton’s range to conform to the distal edge of the tumor. This
technology was used at several proton facilities including the Hahn-MeitnerInstitut (HMI) in Berlin (109, 110) and at Massachusetts General Hospital (MGH)
(111, 112) The latter type of range degrader was built in order to localize the
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distal edge of the proton spread out Bragg peak (SOBP) with a high degree of
precision.

4.2.2 Preliminary determination of depth variation
Construction of the external collimation system required some knowledge
of the magnitude of daily or inter-fractional and intra-fractional beam range
corrections. The wedges had to be large and steep enough to correct for the
majority of anatomic variations and calculation based variations encountered
during a patient’s fractionated radiotherapy. To estimate the range of variations
in actual patient treatment, we measured the distance from the abdomen to
anterior rectal wall in the mid-sagittal plane near the superior prostate and
proximal seminal vesicles in patients without rectal balloon immobilization (Figure
41).

Previous studies indicate that both interfractional and intrafractional

variation of the target organs was greatest at the level of the seminal vesicles (44,
61).

Figure 41: Measured depth from the abdomen to the anterior rectal wall
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Taking advantage of a previously completed repeat CT imaging research
protocol, the mean depth was calculated for each patient and subtracted from
each weekly CT image set for 30 patients and a total of 154 depth variations.
One standard deviation of variation was 4.5 millimeters (Figure 42). The total
range of beam attenuation for our patient set-up device had to be capable of at
least 9 millimeters (2 standard deviations) range attenuation both anteriorely and
posteriorely to correct for anatomic variation in 95% of cases.

Some additional

margin was added to the nine millimeters to account for potential variation in the
calculated range.
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Figure 42: Measured depth variations to the anterior rectal wall
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The absolute depth to the anterior rectal wall was also important for
wedge design. The mean depth to the anterior rectal wall from the abdomen was
13.8 centimeters with a standard deviation of 1.5 centimeters. The maximum
therapeutic energy of the synchrotron at the PTC was 250 MeV. After scattering,
shifting, and monitoring in the nozzle, the maximum range of this energy was
approximately 28.5 centimeters. Considering the depth to the target, the wedges
could be no more than 11-12 centimeters in height.

4.2.2 Wedge system design
The relationship between the wedge dimensions and the total range of
attenuation was illustrated in Figure 43. In the wedges’ reference position, the
total physical thickness of the wedge was the product of the wedge length and
the tangent of the wedge angle, or the maximum height of the wedge. The
distance that the dynamic wedge can travel was limited by the need to maintain a
uniform thickness across the beam. Thus, the maximum and minimum depths
were limited by the length of the wedges and the width of the treatment beam.
For the case for prostate treatment, we assumed that the width of the beam
would be approximately 10 centimeters. The total attenuation range was the
difference in the length of the wedges and the beam multiplied by the tangent of
the wedge angle.
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Figure 43: Relation of attenuation range to wedge width and angle
We selected a wedge angle of 26.5 degrees. The tangent of this angle
was one-half. The physical thickness of the wedges would change by exactly
one-half the distance the dynamic wedge was moved into or out of the field. For
our prototype design, we created 20 centimeter square wedges that were 10
centimeters in height. These dimensions allowed for 2.5 centimeter correction in
either direction.

In hindsight, we should have created these wedges slightly

smaller. Additional attenuation added distal edge degradation, additional lateral
scatter, and generated additional neutrons.
After determining the dimensions of the dual wedge range shifter, we
selected an appropriate commercial stepping motor, controller, and mountable
slide. The Velmex Bislide (Velmex, Inc., Bloomfield, NY) commercial system fit
our specifications (Figure 44). The total travel length of the motor was 10 inches.
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The motor’s precision was approximately 1/1000”, ensuring that the precision of
our range shifter would meet our criteria as long as the wedges were well
constructed. The screw index was one tenth of an inch per revolution. The
stepper motor also included commercial software; however, Labview was used to
interface the range shifter with the beam detector in our experimental setting for
future interfacing with our detector from aim 1.

Figure 44: Velmex Bislide stepper motor
We built a custom attachment from the motor carriage of the Velmex
Bislide to the top wedge (Figure 46).

The bottom wedge was inverted and

attached to the bottom side of our measurement cart to achieve uniform range
modulation across the field (Figure 45). Our measurement cart had a second
rack below the wedges to place phantoms for measurement.
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Figure 45: Mobile cart for mounting wedge system

Figure 46: Wedge mounted to the carriage of the stepper motor
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4.2.3 Experimental methods
The first experiment determined the water equivalent thickness of our dual
wedge range shifter. The proton beam was set to 23.5 cm depth. A TG-51
single axis water phantom and Markus parallel plate ionization chamber were
positioned beneath our wedges on our cart rack (Figure 47). The proton depth
dose through the distal falloff was measured with the wedges in place (10 cm
physical thickness) and with the wedges replaced with calibrated solid water
blocks of 6 cm thickness. The measured range of the depth dose with the 6
centimeters of calibrated Lucite build-up material was subtracted by 6 cm to
determine the range of the beam without any buildup material in place. The
difference between this value and the measured range of the beam with the
wedges in place yielded the total water equivalent thickness of the wedges. By
dividing this value by ten centimeters, the total thickness of the wedges, the
relative water equivalent thickness of the Lucite in our wedges was calculated.
This value was necessary for calculating the distance to move our motor to
generate a desired adjustment in depth.
We then calculated the distance necessary to move the motor to shift the
proton beam by a calculated -1cm, -5 mm, 5 mm, and 1 cm in depth (greater
than 2 SD from Figure 42).

These values were twice the desired range

adjustment due to the angle of the wedge divided by the relative water equivalent
thickness of our wedges.

After adjusting the proton beam by our calculated

amounts from our reference position, the depth dose was measured in our
scanning water phantom.

The depth of R50 was then estimated by linear
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integration between our measurement points and these depths were compared
to those predicted by our calculation. The deviation between the range that we
calculated and the measured range would generate the error in the range
correction. The standard deviation of these errors was an independent source of
uncertainty for determination of the composite distal margin in aim 3.

Figure 47: Experimental set-up for wedge precision
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4.3 Results
4.3.1 Calculation of the RWET of the wedge system
Verification of the total WET of the wedges in reference
position
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Figure 48: Calculation of RWET of wedges from measurements

Figure 48 illustrated the two depth dose curves measured to determine the
relative water equivalent thickness of the wedges. The blue series was the depth
dose with the 6 centimeters of water equivalent material in the beam. The red
series was the depth dose with the wedge in the reference position (10
centimeters physical depth). The green series was the depth dose with the 6
centimeters of build-up material that has been shifted by 5.6 centimeters for
visual reference. As shown in the figure, the distance to agreement between the
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two relations was 5.6 cm resulting in a measured total WET of 11.6 centimeters
and a RWET of 1.16 when compared to water.

4.3.2 Wedge precision determination
Measured Depth Dose after the Calculated Correction of 1cm
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Figure 49: Measured depth dose curves after calculated shifts
Figure 49 illustrated the measured depth dose curves after a calculated
shift of -10, -5, 5, and 10 millimeters.

For each curve, the 50% range was

estimated by linear interpolation between the data points. These values were
then compared with the estimated 50% range on the reference depth dose curve.
The absolute distance to agreement between the measured 50% range and the
calculated shifts were shown next to each curve. Additionally, the calculated
range shifts were highly correlated with the measured shifts (Figure 50). The
standard deviation of the distance to agreement was 0.04 mm.
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Figure 50: Correlation of calculated and measured depth dose

4.4 Discussion
4.4.1 Summary
Custom inverted Lucite wedges were designed to degrade the range of
the proton beam to precisely match the distal edge of the target organs. The
dimensions of these wedges balanced attenuation range with size, compatibility
with proton gantry, proton range limit, wedge cart, and treatment couch.The total
WET of the wedges was first determined. Then the distance was calculated to
adjust the proton’s range. This pre-determined shift was a surrogate for the
detector signal and subsequent depth measurement from our detection device
discussed in the previous chapter. One standard deviation of agreement was
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0.04 millimeters. This figure is negligible compared to the in vivo and in vitro
uncertainties of the detector.

4.4.2 Study limitations
One issue that was not addressed during the testing of our aim was the
time effect between when the wedges receive a signal and the time that the
range correction actually occurs. With the speed of the controller and motor
along with the screw index, the maximum estimated wedge speed was 1 inch per
second. Compared with the patient’s anatomic variation from bladder and rectal
filling, this speed was more than adequate. However, breathing induced range
variation was not considered. This issue was a limitation of the entire localization
technique since the distal falloff was only measured and corrected once per spill,
or approximately every two seconds.

Further investigation of the effects of

patient breathing on variation of the anatomy in the lower abdomen was needed
before translating this technique into the clinic.
There were two potential solutions to correct for breathing induced proton
range variation. The first was to use an immobilization device that fits completely
around the patient’s anatomy.

Another potential solution was the use of

stereotactic monitoring and localization with a camera system in conjunction with
our endorectal detector to estimate range variations between pulses. The ability
of the wedges to adjust their position relative to a real-time breathing trace from
the Varian RPM system (Varian Medical Systems, Palo Alto, CA) was tested.
The lag between the position input and the time when the motor matched the
position was slightly greater than 100 milliseconds.

However, without
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corresponding data on the magnitude of breathing-induced depth changes and
the correlation of those changes with the patient’s skin surface, this potential
method was speculation.
Another potential improvement of the system would be to add another
dimension of proton beam correction. Additional fibers within the balloon could
detect variation of the depth along the axis of the balloon. Based on difference in
these measured values, a third wedge could be added to rotate the distal edge of
the beam. The impact and feasibility of this technique could be simulated in the
treatment planning system by measuring the rotation of the rectum and target
organs in CT patient data and drawing custom regions of interest as a surrogate
for the third wedge.

4.5 Specific Aim 2 conclusions
A dual wedge Lucite range degrader was designed with the initial goal of 2
millimeter precision, and we demonstrated that our design meets and exceeds
our initial expectations. Considering the precision of both the detector and the
wedges, the range shifting portion of the device should not significantly contribute
to the treatment uncertainty and the residual distal margin needed to ensure
treatment coverage with our localization technique.
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Chapter 5: Dosimetric comparison of IMRT, bilateral proton, and
single anterior proton beam treatment of the prostate
5.1 Introduction
Specific Aim 3: Determine dosimetric benefit of utilizing the in vivo proton
beam detection device and external proton beam range shifter,
Working hypothesis: Using the measured precision of the in vivo proton beam
detection device and external proton beam range shifter, the reduced margin
planning treatment strategies reduce mean rectal dose by 20% over conventional
bilateral proton and IMRT photon therapies.
The conversion of proton stopping power ratio from CT Hounsfield units to
calculate proton range carries large uncertainties, necessitating large distal
margins to ensure target coverage and diminishing the major benefit of proton
therapy. In the case of proton radiotherapy for prostate cancer, the major doselimiting organ is the rectum, which is adjacent to the prostate target. In current
practice, institutions adopt bilateral treatment proton beams to avoid pointing the
sharp falloff of the Bragg peak directly in front of the rectum. Unfortunately, this
beam arrangement introduces higher rectal dose due to the large lateral
penumbra of the proton beam.

Several published studies compare bilateral

proton treatment with photon IMRT of the prostate and reported significant
sparing of the rectum and bladder volume at low doses (113-116). While low
dose sparing of normal tissues is still beneficial to prostate cancer patients, these
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improvements may have minimal effect on acute rectal and bladder toxicity and
may not allow target dose escalation or hypofractionation of treatment.
Methods to detect the anterior beam at depth were developed at this
institution (this thesis) and elsewhere (99, 100) to eliminate the large distal proton
planning margin, enabling abrupt dose falloff at the anterior rectal wall rather than
the relatively shallow falloff of the lateral beam penumbra with conventional bilateral treatments.
The purpose of this chapter is to evaluate the ability of an anterior proton
beam to adequately spare the rectum considering the measured precision of our
in vivo patient set-up technique discussed thus far in the thesis. this treatment
technique will be compared with the conventional treatment planning techniques:
eight-field IMRT and bilateral proton treatment of the prostate. Based on the
estimated rectal dose for patients receiving our technique for their proton
radiotherapy, the thesis hypothesis will be evaluated.

5.2 Materials and methods
5.2.1 Patient protocol
The first twenty-seven prostate cancer patients treated with proton therapy
at this institution enrolled in an IRB-approved prospective treatment planning
study to compare standard IMRT and bi-lateral proton treatments with a single
anterior proton beam treatment. An additional treatment plan was generated to
simulate patient treatment with an anterior proton beam with a reduced distal
margin. All twenty-seven patients had localized cancer of the prostate (T1-T3,
N0, M0) prescribed to 75.6 CGE in 42 treatment fractions.

Patients were
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immobilized with the Dual Leg Positioner (Cisco Systems, San Jose, CA) and
marked with external skin fiducials for treatment alignment with the in-room
lasers. All patients were instructed to maintain a full bladder and empty bowel.
Endorectal balloons (MEDRAD, Inc., Pittsburgh, PA) were inserted into each
patient’s rectum to provide additional prostate immobilization, expand the rectal
volume, and push the upper bowel out of the treatment field. A single CT data
set was created for each patient, contoured by a single physician (AKL), and
exported into treatment planning systems for plan generation. The rectum was
contoured from the anus to the recto-sigmoid flexure.

The rectal wall was

generated by contracting the rectal contour by 3 mm and generating an ROI
between the rectal contour and contracted contour.

The bladder wall was

generated identically to the rectal wall.

5.2.2 Treatment planning
For the patients’ proton radiotherapy treatment, reference CT data sets
were imported into Varian’s Eclipse treatment planning system.

Each daily

fraction was delivered with equally weighted parallel-opposing passively
scattered proton beams as illustrated in the middle of Figure 51. Bilateral proton
beam treatment margins were generated with our standard institutional margin
recipes. The lateral aperture margins for both the bilateral treatment plans and
anterior proton beam treatment plans included allowances for set-up uncertainty
(2mm), patient motion (3mm), and proton lateral beam penumbra (12 mm) for a
total of 17 mm. The distal and proximal margins accounted for uncertainties in
converted CT Hounsfield units to proton stopping power. For the bilateral plans,
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generation of these margins included 3.5% of the proton depth plus a 3 mm
machine-dependent beam energy uncertainty for a total of 10-13 mm distally and
8-10 mm proximally. The distal margin for the anterior proton beam treatment
was 2 mm to account for the estimated precision of the in vivo proton beam
detection method we discussed in the previous two chapters. By measuring the
beam at depth, we avoid the 3.5% of the depth distal margin because we have
not calculated the beam pathlength from CT Hounsfield units. Since we detect
the beam during each proton spill, we also avoid set-up and interfractional motion
uncertainties. The proximal margins of the anterior proton beam plans were also
set to 2 millimeters.

The compensator smearing corrected for movement of

tissue heterogeneities in the beam path by assuming the water equivalent depth
to the distal edge of the target at any point is the maximum of its neighbors within
the smearing radius. Determination of the smearing radius included the square
root of the square of 3% of the target depth added with the square of set-up and
motion uncertainties for a total of 8-10 mm. The smearing margin for the anterior
beam plans was maintained at 7 mm.
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IMRT

Proton-Conv

Axial

Proton-AP

Axial

Axial
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Sagittal

Sagittal
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Figure 51: A dosimetric comparison between IMRT, bilateral proton therapy,
and anterior beam proton therapy
CT data was imported into Phillip’s Pinnacle treatment planning software
for IMRT treatment planning generation.

The IMRT PTV included an 8 mm

isotropic expansion of the prostate except along the posterior border which was 5
mm (Figure 51: Left). The prescription dose was 75.6 CGE (shown in red). The
IMRT treatment plans were optimized to spare normal tissue dose in the rectum
and bladder at dose levels of 70, 60, and 40 Gy. Additional constraints were set
to prevent hotspots in the femoral head and general normal tissue. The dose to
the CTV was normalized to 100% coverage on the IMRT and bilateral treatment
plans. In some case, complete coverage of the CTV was challenging with a 2
mm margin anterior plan due to the approximation of the compensator before
accounting for scatter. In these cases, the compensator was manually modified
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and the treatment prescription set to a comparable level as the bilateral proton
plans.
Additionally, we generated anterior proton plans with varying distal
margins on a single patient to evaluate the effectiveness of treatment is our in
vivo beam detection is more precise (down to 0 mm margin) or less precise ( as
much as 5 mm margin) than we originally anticipated.

With the known

relationship of distal margin to mean dose to the rectum, the treatment planning
results (2 mm margin) can be extrapolated to the anterior treatment with a margin
reflecting the measured precision of our device (2.4 mm).

5.2.3 Data analysis
Each patient’s dose volume histograms for the prostate, proximal seminal
vesicles, rectum, bladder, rectal wall, and bladder wall were collated in MATLAB
and exported to Excel for data analysis. A single dose population histogram was
generated for each organ in each treatment arm to illustrate the average relative
volume exposed to a dose level. The terms Grey and cobalt-grey-equivalent
were used interchangeably in this study. The relative biological value used for
clinical proton treatment at our institution was 1.1.

The dose levels were

generated in 10 cGy bins for display in the dose population histograms. For each
patient and organ, the maximum dose, mean dose, and median dose was
recorded. For the prostate and proximal seminal vesicles, the minimum dose to
0.1 cc was recorded as well. The average, standard deviation, minimum, and
maximum of each of those dose metrics was summarized in tabular form. To
statistically compare our treatment arms for each organ, p-values were
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generated with the student t-test for each dose bin between each treatment arm
for each critical organ. These results were displayed graphically relating the
probability of any treatment arm pairing to be statistically the same at each dose
bin. These graphs were called P-plots.

5.3 Results
5.3.1 Target organ coverage
Table 2 summarizes the dosimetric statistics for the prostate and the
proximal seminal vesicles across our entire 27 patient group. Volume, mean
dose, median dose, maximum dose, and minimum dose are displayed for each
treatment arm and organ of interest.

For each metric the statistical mean,

standard deviation, minimum, and maximum describing the 27 patients were
generated.

Prostate coverage was comparable between the three treatment

arms. Scatter from the pubic symphysis resulted in small hot spots in the middle
of the prostate for some patients. A single statistical outlier had a maximum
hotspot of 87.3 CGE which was reflected in the mean hot spot over the 27
patients (81.1 CGE for Anterior proton versus 80.3 CGE for IMRT and 79.3 CGE
for bilateral proton treatments). The anterior proton plan appears more
heterogeneous, however many clinicians feel that the relative hot and cold spots
on proton plans in general average over a fractionated treatment due to the
sensitivity of the dose distribution to registration errors of heterogeneities in the
beam path. The invariance of the dose distribution assumed in photon treatment
does not apply for proton treatments.
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Average
Prostate

1SD

Max

Min

Total Volume (cc)

66

18

108

38

IMRT

Max Dose (0.1cc)
Mean Dose
Min Dose (0.1cc)
Median Dose

80.3
78.5
76.7
78.5

1.0
0.5
0.4
0.5

82.8
80.0
77.6
80.0

78.9
77.6
76.0
77.6

Bilateral

Max Dose (0.1cc)
Mean Dose
Min Dose (0.1cc)
Median Dose

79.3
77.9
76.5
77.8

0.5
0.3
0.3
0.3

80.6
78.7
77.2
78.7

78.1
77.2
76.1
77.1

AP

Max Dose (0.1cc)
Mean Dose
Min Dose (0.1cc)
Median Dose

80.9
77.9
75.4
77.8

1.1
0.4
0.5
0.5

83.3
78.7
76.4
78.7

79.4
76.6
74.1
76.6

Total Volume (cc)

8

3

15

2

IMRT

Max Dose (0.1cc)
Mean Dose
Min Dose (0.1cc)
Median Dose

79.8
78.5
77.1
78.4

0.8
0.5
0.5
0.5

81.7
79.9
77.9
79.9

78.6
77.5
76.1
77.5

Bilateral

Max Dose (0.1cc)
Mean Dose
Min Dose (0.1cc)
Median Dose

78.5
77.6
76.8
77.6

0.5
0.5
0.5
0.5

79.7
78.7
78.0
78.7

77.6
77.0
76.1
76.7

AP

Max Dose (0.1cc)
Mean Dose
Min Dose (0.1cc)
Median Dose

79.7
77.9
76.0
77.8

0.9
0.6
1.4
0.6

81.5
79.5
78.2
79.4

77.9
76.8
70.6
76.8

Proximal SV

Table 2: Dose statistics of the prostate and proximal seminal vesicles
The dose population histograms of the prostate are shown in figure 52.
The IMRT treatment plans appear to be slightly hotter than the bilateral proton
treatment plans; however, these two treatment techniques were both normalized
to receive full treatment coverage to the CTV. The dose population histogram for
the AP proton beam appears troubling at first glance. The Eclipse treatment
planning system had difficulty covering the CTV with a 2 millimeter distal margin
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treatment planning technique.

This is because calculation of the range and

subsequent range compensator generation is made without considering lateral
scatter of the proton beam.

After the full dose calculation is performed, the

effective treatment margin at any one point along the distal edge of the treatment
beam is slightly different from the margin set by the user. This is an inherent
weakness of the treatment planning system rather than an indictment of the
treatment planning strategy.

Some compensation for this miscalculation was

made by manual editing the range compensator and increasing the prescription
isodose line.

Prostate Dose Population Histograms for 27 Patients

Dose (Gy)
Figure 52: Dose population histogram of the prostate
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Proximal Seminal Vesicles Dose Population Histogram

100%
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78

80

82
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Figure 53: Dose population histogram of the proximal seminal vesicles
Figure 53 illustrates the dose population histograms of the proximal
seminal vesicles for our three treatment arms.

The results are similar to those

for the prostate. The mean patient minimum dose to the seminal vesicles was 76
CGE which is slightly better than the 75.4 CGE for the prostate. The dose to the
proximal seminal vesicles with our anterior proton treatment plan was slightly
more heterogeneous than the other two arms.
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5.3.2 Rectum and rectal wall dose
Average
Rectum

1SD

Max

Min

Total Volume (cc)

156

17

196

130

IMRT

Max Dose (0.1cc)
Mean Dose
Median Dose

80.1
31.5
26.5

0.9
4.2
4.5

82.0
38.8
37.7

78.3
22.3
15.6

Bilateral

Max Dose (0.1cc)
Mean Dose
Median Dose

78.5
23.3
7.9

0.7
3.8
5.1

80.3
29.9
19.4

77.1
16.9
0.6

AP

Max Dose (0.1cc)
Mean Dose
Median Dose

79.3
10.5
0.0

1.1
2.3
0.0

83.0
15.7
0.1

77.5
6.9
0.0

Total Volume (cc)

31

4

38

26

IMRT

Max Dose (0.1cc)
Mean Dose
Median Dose

80.0
33.3
23.4

0.9
3.6
3.6

81.9
38.3
31.7

78.2
26.4
15.1

Bilateral

Max Dose (0.1cc)
Mean Dose
Median Dose

78.5
24.6
3.8

0.7
2.9
2.7

80.2
29.7
10.7

77.1
19.8
0.4

AP

Max Dose (0.1cc)
Mean Dose
Median Dose

79.1
16.2
0.0

1.2
2.3
0.0

84.1
21.7
0.0

77.3
12.3
0.0

Rectal Wall

Table 3: Dose statistics of the rectum and rectal wall
Differences in dose to the rectum and the rectal wall were substantial
between our treatment groups (Table 3). Mean dose to the rectum and rectal
wall was greatest in the IMRT group (31.5 and 33.3 CGE) followed by the
bilateral proton group (23.3 and 24.6 CGE) and anterior proton group (16.2 CGE).
Maximum dose was similar between treatment groups. Over half the rectum was
spared in our anterior treatment group (0 CGE) and nearly half in the bilateral
group (median dose of 3.75 CGE).
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Rectal Wall Population DVHs

Rectal Volume Population DVHs

Dose (Gy)
Figure 54: Dose population histograms of the rectal wall and rectum
Figure 54 illustrates the dose population histograms for the rectum
(bottom) and rectal wall (top) for our three treatment techniques. The rectal
sparing is nearly equivalent between bilateral and IMRT treatments except for
low dose regions (sub-30 CGE) where protons substantially outperform IMRT for
both the rectum and the rectal wall.

The anterior treatment achieves nearly
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approximately 10-15% sparing of the rectal wall by volume of conventional
bilateral proton treatment at all dose levels. The dose delivered to the entire
rectum with the anterior proton beam treatment is much less than the bilateral
and IMRT treatment techniques at all dose level less than 70 CGE. The dose to
the rectum is comparable between the IMRT and bilateral proton arms for doses
greater than 40 CGE. The dose to the rectum with the anterior beam planning is
nearly half the dose from the other two treatment arms.
The p-plots provide a visual representation of the statistical significance
between the treatment arms (Figure 55).

The dose population histograms

display error bars illustrating the standard deviation of the data sets at each dose
bin. The standard deviation of the mean (SDM), which is used for determining
the statistical significance, is the standard deviation divided by the square root of
the number of patients. Therefore the SDM is greater than a factor of 5 times
smaller than the standard deviation. In Figure 54, the SDM is extremely small.
Therefore, small dosimetric changes between the treatment groups can change
the statistical significance abruptly.

The abrupt changes of the statistical

significance are represented by the steep gradients of the p-plots. Figure 55
summarizes the statistical differences between our treatment arms for rectal
sparing. The rectal dose for anterior treatment plan is significantly less then
IMRT (red) for all dose level less then 80 CGE (p< 0.01) and less than bilateral
proton for all dose levels less than 77.5 CGE (p < 0.01). The bilateral proton plan
treats significantly less rectum then the IMRT plan for dose levels less than 35.5
CGE and significantly more rectum from 46.7 CGE to 71.4 CGE (p<0.01).

The
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bilateral proton and IMRT plans are nearly equivalent at doses near prescription
levels.
Rectum Student's T Test Comparison
0.2
0.18
0.16
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Figure 55: P-plot of the rectum
The statistical differences in the volume of rectal wall treated by our
treatment arms are summarized in figure 56. As in the case of the rectal volume,
the anterior treatment plan treated less rectal wall than the IMRT plan for all dose
levels and less than the bilateral proton plan for all dose levels less then 77.4
CGE (p < 0.01). The bilateral proton plan treated less rectal wall than the IMRT
for dose levels less than 41.4 CGE and greater than 73.3 CGE (p < 0.01).
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Figure 56: P-plot of the rectal wall for all three treatment techniques
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5.3.3 Bladder and bladder wall dose
Average
Bladder

1SD

Max

Min

Total Volume (cc)

335

141

620

133

IMRT

Max Dose (0.1cc)
Mean Dose
Median Dose

80.0
19.0
8.0

0.9
6.4
6.7

82.0
33.1
24.6

78.1
8.8
1.9

Bilateral

Max Dose (0.1cc)
Mean Dose
Median Dose

78.7
14.7
1.2

0.6
5.7
4.2

79.9
31.2
21.8

77.6
7.5
0.0

AP

Max Dose (0.1cc)
Mean Dose
Median Dose

80.1
22.1
8.9

1.2
9.4
16.8

82.9
43.4
58.9

77.2
8.8
0.0

Total Volume (cc)

57

18

94

28

IMRT

Max Dose (0.1cc)
Mean Dose
Median Dose

79.8
19.8
7.4

0.9
6.0
6.5

81.9
33.4
25.0

78.1
10.2
1.7

Bilateral

Max Dose (0.1cc)
Mean Dose
Median Dose

78.7
16.6
0.8

0.6
5.4
3.0

79.9
30.5
15.6

77.6
8.8
0.0

AP

Max Dose (0.1cc)
Mean Dose
Median Dose

80.1
22.7
7.8

1.2
8.7
15.1

82.8
40.1
50.6

77.7
9.6
0.0

Bladder Wall

Table 4: Dose Statistics of the Bladder
Dose to the bladder wall were nearly opposite of the rectal wall dose
results (Table 4). The mean dose to the bladder and bladder wall was greatest in
the anterior proton group (22.1 and 22.7 CGE) followed by IMRT group (19.0 and
19.8 CGE) and bilateral proton group (14.7 and 16.6 CGE). The maximum dose
to the bladder and bladder wall were comparable between the IMRT and anterior
proton beam plans and slightly reduced in the bilateral proton beam plans. The
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median dose to the bladder was greater in the anterior treatments than the other
two treatment arms.

100%

Bladder Wall Population
DVHs

80%

IMRT
Proton ‐ Bilateral
Proton ‐ AP only

60%
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20%
0%
0
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80

Bladder Volume Population DVHs

Dose (Gy)
Figure 57: Dose population histograms of the bladder and the bladder wall.
Figure 57 shows the dosimetric comparison of the three treatment
techniques for bladder and bladder sparing. The ability of the bilateral proton
and IMRT plans to spare the bladder is comparable at dose levels greater than
30 CGE. The bilateral plan is slightly better for the low dose regions of the
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bladder and bladder wall. The anterior proton plan delivers approximately 10%
more dose to the bladder wall than IMRT for dose levels greater than 30 Gy and
at all dose levels when compared to bilateral proton treatment.
Bladder Wall Student's T Test Comparison
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Figure 58: P-plot of the bladder wall dose
The statistical differences in the volume of bladder wall treated with our
three treatment technique are summarized in figure 58. The IMRT plan delivered
more dose to the bladder wall than the anterior proton technique for doses less
than 7.8 CGE and less dose from 19.6 to 73.2 CGE (p<0.01). The IMRT plan
delivered more dose to the bladder wall than the bilateral proton technique for
doses less than 31.9 CGE and less dose from 39.8 to 74.1 CGE (p<0.01). The
anterior proton technique treated more bladder wall than the bilateral technique
for all dose levels less than 77.5 CGE (p<0.01).
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Figure 59: P-plot of the bladder
The statistical differences in the volume of bladder treated with our three
treatment technique are summarized in figure 59. The IMRT plan delivered more
dose to the bladder wall than the anterior proton technique for doses less than
6.7 CGE and less dose from 22.8 to 74.9 CGE (p<0.01).

The IMRT plan

delivered more dose to the bladder wall than the bilateral proton technique for
doses less than 38.4 CGE and more volume at levels greater ant 73.5 CGE
(p<0.01).

The anterior proton technique treated more bladder wall than the

bilateral technique for all dose levels (p<0.01).
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4.3.4 Femoral head dose
Femoral Head Dose Population Histogram
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Figure 60: Dose population histogram of the femoral heads
Figure 60 illustrates that femoral head dose is considerably more for
bilateral proton treatment than for standard 8-field IMRT. The mean dose to the
femoral heads with the bilateral treatment techniques was 25.1 CGE and 17 CGE
for the IMRT. However, the patient average maximum dose to 0.1 cc of the
femoral heads was 34.5 CGE for the bilateral proton technique and 41.4 CGE for
the IMRT treatments.

Generally the femoral heads are constrained to a

maximum dose of approximately 45 CGE, so IMRT treatment may be more likely
to illicit morbidity than the bilateral treatment. Anterior beam treatment delivers
nearly zero dose to the femoral heads.
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5.3.5 Rectal dose and distal margin
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Figure 61: Rectal dose volume histogram as a function of distal margin
Figure 61 illustrates the dose volume histograms (DVH) of the prostate
and rectal volume for a single patient calculated from a two field conventional bilateral proton beam plan and a single anterior proton beam plan with distal
margins of 0 to 5 mm. The mean rectal dose is also displayed for each treatment
planning strategy. The mean rectal dose scales linearly with increasing distal
margin, approximately 100 cGy per millimeter.

Although our predicted distal

margin is 2.4 millimeters and our dosimetric study tested a 2 millimeter margins,
we can realistically predict that the mean rectal dose over the 27 patients should
be no more than 100 cGy higher with a 2.4 mm distal margin. Also, this figure
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suggests that the rectal sparing capability of the anterior beam treatment is
preserved even with a 5 mm margin. Table 5 presents the data from Figure 61 in
tabular form. The mean dose, V40, V60, and V70 are displayed for the bilateral
proton and anterior proton plans. For comparison, the values for the anterior
plans were normalized to those of the bilateral plans. The table indicates that the
values of V60 and V70 are more sensitive to the size of the anterior treatment
margin with comparing anterior treatment with bilateral treatment.

Mean Dose

V40

V60

V70

[cGy]

% Bilateral

% Vol

% Bilateral

% Vol

% Bilateral

% Vol

% Bilateral

AP 0mm

481.5

0.25

5.26

0.24

2.75

0.21

1.39

0.19

AP1mm

581.1

0.30

6.54

0.29

3.76

0.29

2.11

0.29

AP2mm

690.1

0.36

7.97

0.36

4.83

0.37

3.01

0.41

AP3mm

798.5

0.42

9.36

0.42

5.98

0.46

3.93

0.54

AP4mm

921.1

0.48

10.91

0.49

7.30

0.56

4.99

0.68

AP5mm

1058.4

0.55

12.64

0.57

8.74

0.67

6.28

0.86

Bilateral

1912.4

1.00

22.33

1.00

13.10

1.00

7.29

1.00

Table 5: Table of rectal dose as a function of anterior proton beam margin
size

5.4 Discussion
5.4.1 Summary
In this chapter, we set out to compare the dosimetric impact of IMRT and
passively scattered bilateral proton beam treatment and investigate the utility of
anterior beam proton treatment utilizing the proton’s rapid distal fall-off for optimal
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rectal sparing. The previous two chapter outlined methods to detect the anterior
beam at depth. These methods eliminated the distal proton planning margin,
enabling abrupt dose falloff at the anterior rectal wall rather than the shallow
falloff of the lateral beam penumbra with bi-lateral treatments.
The first 27 prostate cancer patients treated with protons at this institution
enrolled in a prospective treatment planning study to compare the three
treatment techniques. Based on the measured precision in the previous two
chapters, we estimated that we needed a 2.4 millimeter treatment planning
margin to ensure treatment coverage. We relaxed our 95% confidence criteria to
90% and applied a 2 mm distal margin for anterior proton beam planning based
on our initial hypothesis. The anterior beam treatment significantly spared the
rectum and anterior rectal wall more than the IMRT and bilateral beam
treatments at all dose levels.

However, bladder and bladder wall dose was

greater in the anterior beam treatment than IMRT and bilateral beam treatments
nearly all dose levels. No dose was delivered to the femoral heads with the
anterior beam treatment while the IMRT and bilateral proton treatments delivered
a mean dose of 17.0 CGE and 25.1 CGE to the femoral heads respectively.

5.4.2 Study limitations
Delivery of a highly conformal proton treatment plan with the Eclipse
treatment planning system was challenging because of approximations made
during the generation of the range compensator. Varian upgraded their software
once during this experiment, and the resulting anterior proton plans were
noticeably more homogeneous with the updated software. When the user set a
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particular margin for the target organs, the distance of the prescription isodose to
the target organ should be close to this value at all points along the distal target.
However, the residual distance between the target and prescription isodose did
not always match the specified distal margin. Although the CTV was not always
100 % covered by the anterior plan, the normal tissue dose could potentially be
lower with improved software. The TPS generated cold spots were compensated
by increasing the dose delivered to the tumors, which in turn generated many
hotspots. The compensator was manually edited in problematic areas, greatly
increasing the range of the beam in nearby areas where additional margin was
not necessarily needed.

5.4.3 Previous dosimetric comparisons
Several authors have investigated the potential of proton therapy relative
to IMRT with dosimetric planning studies. Lomax (113) compared proton and
photon intensity modulated radiotherapy in nine different patients with a variety of
treatment legions including one patient with metastasizing prostate carcinoma
treated with a single anterior spot-scanning proton beam.

All plans included

planning target margins as indicated in ICRU 50 and additional corrections were
made for tissue inhomogeneities in the beam path.

They reported greater

treatment homogeneity in the target volume and nearly a three-fold reduction in
the volume of normal tissue at 30% of the prescription for anterior proton
treatment over 4-field conformal photon and 9-field IMRT. Dmean and V50% were
less for proton treatment over conformal photon and IMRT for all organs at risk;
however maximum dose and V70% were comparable between proton treatment
128

and IMRT. Interestingly, rectum was not included as an organ-at-risk for this
patient. Since this particular study treated to a relatively large fraction of the
pelvis when compared with our treatment target, it was difficult to draw
comparisons between the results.
Cella et al (117) compared 3D conformal photon, bilateral proton, 5 field
IMRT, and 5 field IMPT treatments for a single patient. The PTV margin was a 1
cm expansion of the prostate and SV except at the rectal interface where the
margin was 6 mm. Both proton arms exhibited increased homogeneity in the
target and subsequently greater estimated TCP (95% versus 93%).

Rectal

sparing was increased at all dose levels below V80% by the proton treatments.
Authors estimated NTCP for late grade-three rectal toxicity with dose escalation
to 99 Gy to be 4.7% for IMRT and 3.9% for IMPT. This study used geometric
margins for their proton plans which resulted in a much more conformal
treatment plan. Therefore the comparison with their intensity-modulated proton
plan was not very useful. Their bilateral proton plan was comparable to our own
since our lateral margins are set with a geometric expansion. After rescaling
their dose volume histogram, the rectal dose on their patient was comparable to
our dose population histogram.

However, their IMRT results were extremely

different. They excluded the anterior rectum from the PTV, resulting in nearly no
volume of the rectum receiving dose in excess of 90% prescription. Their IMRT
plan also appeared less conformal to the rectum at moderate dose levels (~ 50%
prescription), and the bilateral consequently spares much more of the rectum
than predicted in our study.
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Mock et al (114) compared bilateral proton, 4-field conformal photon, and
7 field IMRT treatments for 5 prostate cancer patients simulating different
disease stages by including no SV, proximal SV, or entire SV in the treatment
volume. The PTV was generated with a uniform 5 mm expansion of the CTV.
Inclusion or exclusion of the SV made little difference in the relative dosimetry
between the treatment arms. Proton treatment substantially decreased integral
dose at the cost of decreased dose homogeneity in the PTV. Proton treatment
provide near equivalent femoral head sparing to IMRT, slightly increased bladder
sparing, and substantially increased sparing to the rectal wall (~ absolute
reduction of 20% at V50% and 10% at V90%). This study’s methods were closer to
our own study. The 5 millimeter clinical target volume expansion they utilized
was comparable to our lateral margin; however their IMRT plans spared the
rectum considerably less than in our study. Their rectal DVH for the bilateral
proton plans were very similar to our own.
Muzik et al (118) compared static and dynamic MLC linac-based IMRT,
helical tomotherapy , and spot-scanning proton therapy (2 lateral-oblique beams)
for a single deep seated prostate case. Again, their rectal dose for their proton
treatment was similar, but their photon therapy rectal doses were considerably
higher than our own.
Trofimov et al (115) compared IMRT, bilateral proton therapy, and IMPT
for 10 prostate cancer patients. They included compensator smearing in addition
to the traditional planning treatment margins for the target organs. Comparison
of their IMRT and bilateral treatment arms was similar to our own results. They
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found little difference between the two treatment techniques for all doses in
excess of 40 Gy. Their bladder dose results were also similar to our study. They
found that the bladder dose in the bilateral proton arm was slightly higher on
average from 40 Gy to prescription dose than in the IMRT arm and less at low
doses.
Vargas et al (116) reported the rectal and bladder doses of the first 10
sequentially treated proton cancer patients at their institution. They set a 5mm
axial PTV expansion and an 8 mm expansion cranial-caudally. They optimized
the proton beam angles to maximally spare the rectum and bladder. They also
reduced the lateral aperture margin from 1 cm to 7-8 mm posteriorely. The
optimization in beam angle along with the reduction in the lateral aperture at the
rectum led to significantly more rectal sparing than in our study.

5.4.4 Bladder and rectal toxicity
The use of the anterior proton therapy beam for prostate treatment has
some potential limitations as well. The most obvious limitation is the increased
bladder dose. A series of studies at our institution have modeled GU and GI
toxicity as functions of bladder and rectal dose respectively (75, 78, 119).
Results of these studies suggested that the strongest determinant of late bladder
toxicity was the dose to the hottest 2.9% of the bladder. The determinants of late
rectal bleeding were uncertain, however, the rectum did appear to exhibit a
strong dose-volume effect.

These two results in combination suggested a

therapeutic gain by reducing the rectal dose-volume at the cost of some bladder
dose. However, these studies enrolled 3D-CRT patients without the use of a
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rectal balloon and therefore may not adequately predict the occurrence and GU
and GI toxicity in highly conformal therapy utilizing rectal balloons which can
dramatically alter rectal dose(120-122). Oncologists will have to use their own
discretion when choosing suitable treatment planning strategies until additional
investigations addressing GU and GI toxicity in proton therapy prostate patients
with rectal balloons are published.

5.4.5 RBE enhancement in the SOBP
Protons have comparable treatment effect as photons; however, a slight
adjustment to the prescription is necessary to account for the slight difference in
the relative biological effectiveness (RBE) of protons relative to equivalent photon
dose.

The dose delivered with proton treatment must be corrected with the

experimentally determined RBE and which will convert dose delivered in Gray to
cobalt grey equivalent (CGE) dose.

The generally accepted value for the RBE

of protons in the clinical therapeutic range is 1.1, however there is some
uncertainty in this experimentally determined value, particularly at the distal edge
of a proton SOBP (123). In vivo measurement estimates this enhancement at
approximately 10%. In vitro studies have estimated distal RBE as great as
1.4.(124)

RBE enhancement at the rectal wall could be problematic; however,

there is a simultaneous dose fall-off in this region as the intensity of the proton
beam drops off. Depending on the safety margin used in our in vivo feedback
system, it is unclear which factor (RBE enhancement vs. rapid dose falloff) will be
the dominant factor for the rectal wall. Nevertheless, this 1-2 cm dose
enhancement region would benefit for prostate treatment. Biopsy studies have
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shown that tumor foci are preferentially located in the peripheral zone of the
prostate. (125, 126) The potential biological dose enhancement would improve
the therapeutic ratio for proton therapy with an anterior beam arrangement.

5.5 Specific Aim 3 conclusions
In this chapter, the dosimetric benefit of utilizing the in vivo proton beam
detection device and external proton beam range shifter was determined
considering our previous estimation of the technique precision. The estimated
precision from the previous two chapters was 2.4 millimeters. We compared
treatment with a 2 millimeter anterior proton beam with conventional IMRT and
bilateral proton treatments for 90% treatment confidence. Bladder and rectal
dose are similar between current IMRT and bilateral proton prostate treatments
at dose levels above 30-40 CGE. With the implementation of in vivo proton
beam detection, anterior proton beam treatment of prostate is a possible
treatment alternative, substantial sparing dose to the rectum and femoral heads
at the cost of increasing bladder dose. Given the relative amount of sparing of
the rectum and increased bladder dose, we anticipate a therapeutic gain with our
technique.
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Chapter 6: Dissertation conclusion
At the beginning of this thesis, we hypothesized that the use of in vivo
proton beam detection within a rectal balloon and dynamic range modulation of
an anterior proton beam will enable the use of a reduced distal margin, reducing
the mean rectal dose by 20% over conventional bilateral proton treatment and
IMRT. To test this hypothesis a scintillation fluid filled endorectal balloon was
designed for real-time determination of an anterior proton beam’s range. The
goal of 2 millimeter precision was nearly met. The estimated 95% confidence
interval was 2.4 millimeters. A dual wedge Lucite range degrader was designed
with an initial aim of 2 millimeter precision, and the design performance
exceeded our expectations with an estimated 0.04 millimeter precision.

The

dosimetric benefit of utilizing the in vivo proton beam detection device and
external proton beam range shifter was then determined by comparing treatment
with a 2 millimeter anterior proton beam with conventional IMRT and bilateral
proton treatments. The anterior beam treatment exceeded the expectations of
our hypothesis, halving the dose the rectum receives during treatment. With the
implementation of in vivo proton beam detection, anterior proton beam treatment
of prostate is a feasible treatment option, substantial sparing dose to the rectum.
Further work to translate this technology into clinical use should be promptly
completed to reduce incidence of rectal morbidity in patients treated for prostate
cancer with radiation therapy.
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